www.alam-tany.

com

drug – drug
interactions
by

professor ghada hashem

department of pharmacology

faculty of medicine

cairo university
 2005

drug interactions
the administration of one drug (a) can alter the action of another
(b) by one of two general mechanisms:

• modification of the pharmacological effect of b without altering its

concentration in the tissue fluid (pharmacodynamic interaction)

• alteration of the concentration of b that reaches its site of action

(pharmacokinetic interaction).

1) for such interactions to be important clinically it is necessary that

the therapeutic range of drug b is narrow (i.e. that a small reduction in
effect will lead to loss of efficacy and/or a small increase in effect will
lead to toxicity).

2) for pharmacokinetic interactions to be clinically important it is also

necessary that the dose-response curve of drug b is steep (so that a
small change in plasma concentration leads to a substantial change
in effect).

3) for many drugs these conditions are not met: even quite large
changes in plasma concentrations of relatively non-toxic drugs like
penicillin are unlikely to give rise to clinical problems because there is
usually a comfortable safety margin between plasma concentrations
produced by usual doses and those resulting in either loss of efficacy
or toxicity.

4) several drugs do have steep dose-response relationships and a

narrow therapeutic margin and drug interactions can cause major
problems, for example with antithrombotic, antidysrhythmic and anti-
epileptic drugs, lithium and several antineoplastic and
immunosuppressant drugs.

n.b. a third category of pharmaceutical interactions should be

mentioned, in which drugs interact in vitro so that one or both are
inactivated. no pharmacological principles are involved, just
chemistry. an example is the formation of a complex between
thiopentone and suxamethonium, which must not be mixed in the
same syringe. heparin is highly charged and interacts in this way with
many basic drugs; it is sometimes used to keep intravenous lines or
cannulae open, and can inactivate basic drugs' if they are injected
without first clearing the line with saline.
pharmacodynamic interaction

pharmacodynamic interaction can occur in many different ways. there

are many mechanisms, and some examples of practical importance
are probably more useful than attempts at classification. consider the
following:

• β-adrenoceptor antagonists diminish the effectiveness of β-receptor

agonists, such as salbutamol or terbutaline.

• many diuretics lower plasma potassium concentration, and thereby

enhance some actions of digoxin and predispose to glycoside toxicity.

• monoamine oxidase inhibitors increase the amount of

norepinephrine stored in noradrenergic nerve terminals and thereby
interact dangerously with drugs, such as ephedrine or tyramine that
work by releasing stored norepinephrine. this can also occur with
tyramine-rich foods—particularly fermented cheeses such as
camembert.

• warfarin competes with vitamin k, preventing hepatic synthesis of

various coagulation factors. if vitamin k production in the intestine is
inhibited (e.g. by antibiotics), the anticoagulant action
of warfarin is increased. drugs that cause bleeding by distinct
mechanisms (e.g. aspirin, which inhibits platelet thromboxane a2
biosynthesis and can damage the stomach) increase the risk of
bleeding caused by warfarin.

• sulphonamides prevent the synthesis of folic acid by bacteria and

other microorganisms; trimethoprim inhibits its reduction to
tetrahydrofolate. given together the drugs have a synergistic action of
value in treating pneumocystis carinii.

• non-steroidal anti-inflammatory drugs (nsaids), such as ibuprofen or

indomethacin, inhibit biosynthesis of prostaglandins, including renal
vasodilator/natriuretic prostaglandins (pge2, pgi2). if administered to
patients receiving treatment for hypertension, they cause a variable
but sometimes marked increase in blood pressure, and if given to
patients being treated with diuretics for chronic heart failure can
cause salt and water retention and hence cardiac decompensation.

n. b. the interaction with diuretics may involve a pharmacokinetic

interaction in addition to the pharmacodynamic effect described here,
because nsaids can compete with weak acids, including diuretics, for
renal tubular secretion (see below).

• h1-receptor antagonists, such as mepyramine, commonly cause

drowsiness as an unwanted effect. this is more troublesome if such
drugs are taken with alcohol, and may lead to accidents at work or on
the road.

pharmacokinetic interaction

all of the four major processes that determine the pharmacokinetic

behaviour of a drug—absorption, distribution, metabolism and
excretion—can be affected by co-administration of other drugs. some
of the important mechanisms are given here, with examples.

i) absorption

1gastrointestinal absorption is slowed by drugs that inhibit gastric

emptying, such as atropine or opiates, or accelerated by drugs
(e.g. metoclopramide) which hasten gastric emptying.

2alternatively, drug a may interact with drug b in the gut in such a

way as to inhibit absorption of b, e.g.
a) calcium (and also iron) forms an insoluble complex with
tetracycline and retards its absorption

b) cholestyramine, a bile acid binding resin used to treat

hypercholesterolaemia, binds several drugs (e.g. warfarin, digoxin)
preventing their absorption if administered simultaneously.

c) addition of epinephrine to local anesthetic injections: the resulting

vasoconstriction slows the absorption of the anaesthetic, thus
prolonging its local effect.

ii) distribution

1displacement of a drug from binding sites in plasma or tissues

transiently increases the concentration of free (unbound) drug,
but this is followed by increased elimination so a new steady
state results, in which total drug concentration in plasma is
reduced but the free drug concentration is similar to that before
introduction of the second 'displacing' drug.

2there are several direct consequences of potential clinical

importance:
1) toxicity from the transient increase in concentration of free drug,
before the new steady state is reached.

2) if dose is being adjusted according to measurements of total

plasma concentration, it must be appreciated that the target
therapeutic concentration range will be altered by coadministration of
a displacing drug.

3) when the displacing drug additionally reduces elimination of the

first, so that not only is the free concentration increased acutely, but
also chronically at the new steady state, severe toxicity may ensue.

4) though many drugs have appreciable affinity for plasma albumin

and therefore might potentially be expected to interact in these ways,
there are rather few instances of clinically important interactions of
this type.

5) protein-bound drugs that are given in large enough dosage to act

as 'displacing agents' include aspirin and various sulphonamides, as
well as chloral hydrate whose metabolite, trichloracetic acid, binds
very strongly to plasma albumin.
6) displacement of bilirubin from albumin by such drugs in jaundiced
premature neonates could have clinically disastrous consequences:
bilirubin metabolism is undeveloped in the premature liver, and
unbound bilirubin can cross the blood-brain barrier (which is also
incompletely developed) and cause kernicterus (staining of the basal
ganglia by bilirubin). this causes a distressing and permanent
disturbance of movement known as choreoathetosis, characterised
by involuntary writhing and twisting movements in the child.

7) phenytoin dose is adjusted according to measurement of its

concentration in plasma, and such measurements do not routinely
distinguish bound from free phenytoin (that is, they reflect the total
concentration of drug). introduction of a displacing drug in an epileptic
patient stabilised on phenytoin reduces the total plasma phenytoin
concentration owing to increased elimination of free drug, but no loss
of efficacy because the concentration of unbound (active) phenytoin
at the new steady state is unaltered. if it is not appreciated that the
therapeutic range of plasma concentrations has been reduced in this
way, an increased dose may be prescribed resulting in toxicity.

8) there are several instances where drugs that alter protein binding
additionally reduce elimination of the displaced drug, causing
clinically important interactions:
a) phenylbutazone displaces warfarin from binding sites on albumin
and more importantly selectively inhibits metabolism of the
pharmacologically active s isomer (see below), prolonging
prothrombin time and resulting in increased bleeding.

b) salicylates displace methotrexate from binding sites on albumin

and reduce its secretion into the nephron by competition with the
anion secretory carrier.

c) quinidine and several other antidysrhythmic drugs including

verapamil and amiodarone displace digoxin from tissue-binding sites
while simultaneously reducing its renal excretion, and can
consequently cause severe dysrhythmias due to digoxin toxicity.

iii) metabolism
some examples of drugs that inhibit or induce drug metabolism are
shown in the following table:
 examples of drugs that induce or inhibit drug-metabolising enzymes
enzyme induction
drugs whose metabolism is affected drugs modifying enzyme action
warfarin phenobarbitone and other
barbiturates
oral contraceptives
rifampin
corticosteroids
griseofulvin
cyclosporin
phenytoin
as well as drugs listed in left-hand column)
ethanol

carbamazepine
enzyme inhibition
drugs whose metabolism is affected drugs modifying enzyme action
warfarin disulfiram
mercaptopurine, azathioprine allopurinol
suxamethonium, procaine ecothiopate and other
anticholinesterases
phenytoin chloramphenicol
various drugs, e.g. tricyclic antidepressants, cyclophosphamide corticosteroids
many drugs, e.g. amiodarone, phenytoin, pethidine cimetidine
pethidine mao inhibitors
cyclosporin, theophylline erythromycin
heophylline ciprofloxacin

1) enzyme induction

1over 200 drugs cause enzyme induction and thereby decrease

the pharmacological activity of a range of other drugs.

2induction (stimulation) of cytochrome isozymes in the liver and

small intestine can be caused by drugs such as barbiturates,
carbamazepine, glutethimide, phenytoin, primidone, rifampin,
and troglitazone.

3since the inducing agent is normally itself a substrate for the

induced enzymes, the process can result in slowly developing
tolerance.

4although this pharmacokinetic kind of tolerance is generally less

important clinically than tolerance that results from
 pharmacodynamic adaptations (e.g. to opioid analgesics), and
the lethal dose of inducing drugs such as the barbiturates is
only moderately increased in chronic users.

5many clinically important drug interactions result from enzyme

induction, a few of which are listed in the above table.

6examples:
a) the antibiotic rifampin, given for 3 days, reduces the effectiveness
of warfarin as an anticoagulant.

b) conversely, enzyme induction can increase toxicity of a drug

whose toxic effects are mediated via a metabolite. paracetamol
toxicity is the case: it is due to n-acetyl-p-benzoquinone imine, which
is formed by cytochrome p450. consequently the risk of serious
hepatic injury following paracetamol overdose is increased in patients
whose cytochrome p450 system has been induced, for example by
chronic use of alcohol. it is likely that part of the variability in rates of
drug metabolism between individuals results from varying exposure
to environmental contaminants, some of which are strong enzyme
inducers.

7enzyme induction can be exploited therapeutically, by

administering phenobarbitone to premature babies to induce
glucuronyl transferase, thereby increasing bilirubin conjugation
and reducing the risk of kernicterus.

2) enzyme inhibition

8drugs that may inhibit hepatic microsomal metabolism of other

drugs include allopurinol, amiodarone, androgens,
chloramphenicol, cimetidine, ciprofloxacin, clarithromycin,
cyclosporine, diltiazem, disulfiram, erythromycin, fluconazole,
fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole,
ketoconazole, metronidazole, mexiletine, miconazole,
omeprazole, phenylbutazone. propoxyphene, quinidine,
ritonavir, sulfonamides, verapamil, zafirlukast, and zileuton.

9this can increase the action, of other drugs metabolized by the

enzyme, such effects can be clinically important, examples
 include:
a) interaction between the non-sedating antihistamine terfenadine
and the imidazole antifungal drugs such as ketoconazole and other
drugs that inhibit the cyp3a subfamily of p450 enzymes. this can
result in prolongation of the q-t interval on the electrocardiogram and
a form of ventricular tachycardia in susceptible individuals.

b) grapefruit juice inhibits cyp3a and reduces the metabolism of

terfenadine and other drugs, including cyclosporin and several
calcium channel antagonists.

c) several inhibitors of drug metabolism influence the metabolism of

different stereoisomers selectively. examples of drugs that inhibit the
metabolism of the active s and less active r isomers (s is 4 times
more potent) of warfarin in this way are shown in the following table:

stereoselective and non-stereoselective inhibition of warfarin

metabolism
stereoselective inhibition of clearance of s isomer

1. phenylbutazone
2. metronidazole
3. sulphinpyrazone
4. trimethoprim-sulphamethoxazole (co-trimoxazole)
5. disulfiram
stereoselective inhibition of clearance of r isomer

1. cimetidine
2. omeprazole
non-stereoselective inhibition of clearance of r and s
isomers

amiodarone

d) the therapeutic effects of some drugs are a direct consequence of

enzyme inhibition (e.g. the xanthine oxidase inhibitor, allopurinol,
used to prevent gout xanthine oxidase metabolises several cytotoxic
and immunosuppressant drugs, including mercaptopurine (the active
metabolite of azathioprine), whose action is thus potentiated and
prolonged by allopurinol.
 e) disulfiram, an inhibitor of aldehyde dehydrogenase used to
produce an aversive reaction to ethanol, also inhibits metabolism of
other drugs, including warfarin which it potentiates. metronidazole, an
antimicrobial used to treat anaerobic bacterial infections and several
protozoal diseases also inhibits this enzyme, and patients are
advised to avoid alcohol for this reason.

cytochrome p-450 isozymes: substrates, inhibitors, and

inducers
n.b. cyp3a4 alone is responsible for more than 60% of hhe clinically
prescribed drugs metabolized by the the liver

inducers inhibitors substrates isozyme

charcoal-broiled cimetidine (tagamet)
meat ciprofloxacin (cipro) caffeine 1a2
smoking enoxacin (penetrex) clomipramine (anafranil)
ethinyl estradiol clozapine (clozaril)
fluvoxamine (luvox) flutamide (enlexin)
isoniazid (inh) imipramine (tofranil)*
mexiletine (mexitil) olanzapine (zypyrexa)
norethindrone tacrine (cognex)
tacrine (cognex) theophylline (theo-dur)
zileuton (zyflo) ropinirole (requip)
r-warfarin (coumadin)
zileuton (zyflo)

amiodarone
aminoglutethimide (cordarone) celecoxib (celebrex) 2c9
(cytandren) cimetidine (tagamet) diclofenac (voltaren)
barbiturates clopidogrel (plavix) dronabinol (marinol)
carbamazepine co-trimoxazole flurbiprofen (ansaid)
(tegretol) (bactrim) fluvastatin (lescol)
griseofulvin disulfiram (antabuse) glimepiride
(fulvicin) efavirenz (sustiva) glipizide (glucotrol)?
nafcillin (unipen) fluconazole (diflucan) glibenclamide?
phenytoin fluvastatin (lescol) ibuprofen (motrin)
(dilantin) fluvoxamine (luvox) indomethacin (indocin)
primidone isoniazid (inh) losartan (cozaar)
(mysoline) traconazole montelukast (singulair)
rifampin i (sporanox) naproxen (naprosyn)
(rimactane) ketoconazole (nizoral) phenytoin (dilantin)
metronidazole (flagyl) piroxicam (feldene)
sulfinpyrazone tolbutamide (orinase)
 (anturane) torsemide (demadex)
ticlopidine (ticlid) s-warfarin (coumadin)
zafirlukast (accolate) zafirlukast (accolate)

inducers inhibitors substrates isozyme

amitriptyline (elavil)*
efavirenz (sustiva) carisoprodol (soma) 2c19
felbamate (felbatol) citalopram (celexa)
fluconazole (diflucan) clomipramine (anafranil
fluoxetine (prozac)* diazepam (valium)*
fluvoxamine (luvox) imipramine (tofranil)*
omeprazole (prilosec) lansoprazole (prevacid)
ticlopidine (ticlid) mephenytoin
pantoprazole (protonix)
omeprazole (prilosec)
pentamidine (pentam)
phenytoin (minor
pathway)
proguanil*
rabeprazole (aciphex)
r-warfarin (coumadin)

amitriptyline (elavil)*
note: cyp 2d6 amiodarone carvedilol (coreg) 2d6
appears relatively (cordarone) clomipramine (anafranil)
resistant to chloroquine (aralen) codeine* Ú morphine
enzyme induction. cimetidine (tagamet) desipramine (norpramin)
diphenhydramine dexfenfluramine (redux)
(benadryl) dextromethorphan
fluoxetine (prozac)* dihydrocodeine*
haloperidol (haldol) efavirenz (sustiva)
mibefradil (posicor) encainide
paroxetine (paxil) flecainide (tambocor)
perphenazine (trilafon) fluoxetine (prozac)*
propafenone fluvoxamine (luvox)
(rhythmol) haloperidol (haldol)
propoxyphene(darvon) hydrocodone*
quinacrine imipramine (tofranil)*
quinidine (quinidex) maprotiline
quinine methamphetamine
ritonavir (norvir) metoprolol (lopressor)
sertraline (zoloft) mexiletine (mexitil)
(weak) nortriptyline (pamelor)
terbinafine (lamisil) oxycodone (percocet)
thioridazine (mellaril) paroxetine (paxil)
perphenazine (trilafon)
 propafenone (rhythmol)
propranolol (inderal)
risperidone (risperdal)
thioridazine (mellaril)
timolol (blocadren)
tramadol (ultram)*
trazodone (desyrel)
venlafaxine (effexor)
inducers inhibitors substrates isozyme
aminoglutethimide clarithromycin (biaxin) acetaminophen (tylenol)
(cytandren) cyclosporine (neoral)¤ alfentanil (alfenta) 3a4
barbiturates danazol (danocrine) alprazolam (xanax)
carbamazepine delavirdine (rescriptor) amlodipine (norvasc)
(tegretol) diltiazem (cardizem)¤ amiodarone (cordarone)
dexamethasone erythromycin astemizole*
efavirenz (sustiva) ethinyl estradiol atorvastatin (lipitor)
glutethimide fluconazole (diflucan) bepridil (vascor)
griseofulvin (weak) bromocriptine (parlodel)
(fulvicin) fluoxetine (prozac)* buspirone (buspar)
nevirapine (weak) carbamazepine (tegretol)
(viramune) fluvoxamine (luvox) cisapride (propulsid)
phenytoin grapefruit juice citalopram (celexa)
(dilantin) indinavir (crixivan) clarithromycin (biaxin)
primidone isoniazid (inh) cyclophosphamide
(mysoline) itraconazole cyclosporine (neoral) ¤
rifabutin (sporanox) dapsone
(mycobutin) ketoconazole (nizoral) delavirdine (rescriptor)
rifampin metronidazole (flagyl) dexamethasone¤
(rimactane) methylprednisolone diazepam (valium)
troglitazone mibefradil (posicor) diltiazem (cardizem) ¤
(rezulin) miconazole (monistat) disopyramide (norpace)
nefazodone (serzone) doxorubicin (adriamycin)
nelfinavir (viracept) efavirenz (sustiva)
norethindrone ergotamine (ergomar)
norfloxacin (norflox) erythromycin (e-mycin)
oxiconazole (oxistat) ethinyl estradiol
prednisone etoposide (vepesid) ¤
quinidine (quinidex) felodipine (plendil)
quinine fentanyl (sublimaze)
ritonavir (norvir) finasteride (proscar)
saquinavir (invirase) flutamide (eulexin)
troleandomycin (tao) ifosfamide (ifex)
verapamil (calan) ¤ indinavir (crixivan)
zafirlukast (accolate) isradipine (dynacirc)
zileuton itraconazole (sporanox)
ketoconazole (nizoral)
 lidocaine
loratadine (claritin)
losartan (cozaar)
lovastatin (mevacor)
methadone
methylprednisolone
mibefradil (posicor)
miconazole (monistat)
midazolam (versed)
nefazodone (serzone)
nicardipine (cardene) ¤
substrates
isozyme
nifedipine (adalat) ¤
nimodipine (nimotop) 3a4
nisoldipine (sular) (cont'd)
nitrendipine
paclitaxel (taxol) ¤
pimozi
de (orap)
prednisolone
quetiapine (seroquel)
quinidine (quinidex)
quinine
rifabutin (mycobutin)
ritonavir (norvir)
saquinavir (invirase)
sertraline (zoloft)
sibutramine (meridia)
sildenafil (viagra)
simvastatin (zocor)
tacrolimus (prograf) ¤
tamoxifen (nolvadex)
terfenadine*
testosterone
theophylline (minor
pathway)
triazolam (halcion)
verapamil (calan) ¤
vinblastine (velban) ¤
vincristine (oncovin) ¤
r-warfarin (coumadin)
zolpidem (ambien)

* = drugs with active metabolites

 ¤=substrate for p-glycoprotein

3) haemodynamic effects

1variations in hepatic blood flow influence the rate of inactivation

of drugs that are subject to extensive presystemic hepatic
metabolism (e.g. lignocaine or propranolol). a reduced cardiac
output reduces hepatic blood flow, so negative inotropes (e.g.
propranolol) reduce the rate of metabolism of lignocaine by this
mechanism.

iv) excretion

the main mechanisms by which one drug can affect the rate of renal
excretion of another are: by inhibiting tubular secretion; by altering
urine flow and/or urine ph; by altering protein binding, and hence
filtration.

1) inhibition of tubular secretion:

2probenecid inhibits penicillin secretion and thus prolongs its
action. it also inhibits the excretion of other drugs, including
azidothymidine (azt)

examples of drugs that inhibit renal tubular secretion

drugs whose t1/2, may be affected drugs causing inhibition
probenecid
penicillin sulphinpyrazone
azidothymidine phenylbutazone
indomethacin sulphonamides
aspirin
thiazide diuretics
indomethacin
verapamil
digoxin amiodarone
quinidine
lithium diuretics
frusemide indomethacin
methotrexate aspirin
nsaids

2) alteration of urine flow and ph:

3loop and thiazide diuretics indirectly increase proximal tubular
 reabsorption of li+ (which is handled in a similar way as na+) and
this can cause li+ toxicity in patients treated with lithium
carbonate for mood disorders.

4the effect of urinary ph on the excretion of weak acids and bases

is put to use in the treatment of poisoning, but is not a cause of
accidental interactions.
important drug interactions
1hp = highly predictable. interaction occurs in almost all patients receiving the
interacting combination.

2p = predictable. interaction occurs in most patients receiving the combination.

3np = not predictable. interaction occurs only in some patients receiving the
combination.

4ne = not established. insufficient data available to base estimate of predictability.

clinically documented interactions properties promoting drug or drug

drug interaction group
acetaminophen: [ne] increased formation of
hepatotoxic acetaminophen metabolites (in *chronic alcoholism alcohol
chronic alcoholics). results in enzyme
induction.
acitretin: [p] increased conversion of
acitretin to etretinate (teratogenic). *acute alcoholic
intoxication tends to
anticoagulants, oral: [ne] increased inhibit drug metabolism
hypoprothrombinemic effect with acute (whether person is
alcohol intoxication. alcoholic or not).

cns depressants: [hp] additive or synergistic *severe alcohol-induced

central nervous system depression. hepatic dysfunction may
inhibit ability to
insulin: [ne] acute alcohol intake may metabolize drugs.
increase hypoglycemic effect of insulin
(especially in fasting patients). *disulfiram-like reaction in
the presence of certain
drugs that may produce a disulfiram-like drugs.
reaction:
cephalosporins: [np] disulfiram-like *additive central nervous
reactions noted with cefamandole, system depression with
cefoperazone, cefotetan, and moxalactam. other central nervous
system depressants.
chloral hydrate: [np] mechanism not
established.

disulfiram: [hp] inhibits aldehyde

dehydrogenase.

metronidazole: [np] mechanism not

established.

sulfonylureas: [ne] chlorpropamide is most

likely to produce a disulfiram-like reaction;
acute alcohol intake may increase
hypoglycemic effect (especially in fasting
patients).

clinically documented interactions properties promoting drug or drug

drug interaction group
anticoagulants, oral: [np] increased inhibits hepatic drug- allopurinol
hypoprothrombinemic effect. metabolizing enzymes.

azathioprine: [p] decreased azathioprine

detoxification resulting in increased
azathioprine toxicity.

mercaptopurine: [p] decreased

mercaptopurine metabolism resulting in
increased mercaptopurine toxicity.
digoxin: [np] decreased gastrointestinal *antacids may adsorb antacids
absorption of digoxin. drugs in gastrointestinal
tract, thus reducing
iron: [p] decreased gastrointestinal absorption.
absorption of iron with calcium-containing
antacids. *antacids tend to speed
gastric emptying, thus
itraconazole: [p] reduced gastrointestinal delivering drugs to
absorption of itraconazole due to increased absorbing sites in the
ph (itraconazole requires acid for absorption). intestine more quickly.

ketoconazole: [p] as itraconazole. *some antacids (eg,

magnesium hydroxide
quinolones: [hp] decreased gastrointestinal with aluminum hydroxide)
absorption of ciprofloxacin, norfloxacin, alkalinize the urine
enoxacin (and probably other quinolones). somewhat, thus altering
excretion of drugs
salicylates: [p] increased renal clearance of sensitive to urinary ph.
salicylates due to increased urine ph; occurs
only with large doses of salicylates.

tetracyclines: [hp] decreased

gastrointestinal absorption of tetracyclines.
1) drugs that may increase anticoagulant * metabolism inducible.
effect: anticoagulants,
amiodarone: [p] inhibits anticoagulant * susceptible to inhibition oral
metabolism. of metabolism by cyp2c9.
anabolic steroids: [p] alter clotting factor *highly bound to plasma
disposition? proteins.

chloramphenicol: [ne] decreased dicumarol *anticoagulation response

metabolism (possibly also warfarin). altered by drugs that
affect clotting factor
cimetidine: [hp] decreased anticoagulant synthesis or catabolism.
metabolism.

ciprofloxacin: [ne] decreased anticoagulant

metabolism?

clofibrate: [p] mechanism not established.

danazol: [ne] impaired synthesis of clotting

factors? anticoagulants,
oral (cont'd)
dextrothyroxine: [p] enhances clotting factor
catabolism?

disulfiram: [p] decreased anticoagulant

metabolism.

erythromycin: [ne] probably inhibits

anticoagulant metabolism.

fluconazole: [ne] decreased warfarin

metabolism.

gemfibrozil: [ne] mechanism not

established.

lovastatin: [ne] probably decreased

anticoagulant metabolism.

metronidazole: [p] decreased anticoagulant

metabolism.

miconazole: [ne] decreased anticoagulant

metabolism.

nonsteroidal anti-inflammatory drugs: [p]

inhibition of platelet function, gastric
erosions; some agents increase
hypoprothrombinemic response (unlikely with
diclofenac, ibuprofen, or naproxen).

phenylbutazone: [hp] inhibits anticoagulant

metabolism.

propafenone: [ne] probably decreased

anticoagulant metabolism.

quinidine: [np] additive

hypoprothrombinemia.

salicylates: [hp] platelet inhibition with

aspirin but not with other salicylates; [p] large
doses have hypoprothrombinemic effect.

sulfinpyrazone: [ne] mechanism not

established.

sulfonamides: [ne] inhibit anticoagulant

metabolism; displace protein binding.

thyroid hormones: [p] enhance clotting

factor catabolism.

trimethoprim-sulfamethoxazole: [p] inhibits

anticoagulant metabolism; displaces from anticoagulants,
protein binding. oral (cont'd)

see also alcohol; allopurinol.

2) drugs that may decrease anticoagulant

effect:

aminoglutethimide: [p] enzyme induction.

barbiturates: [p] enzyme induction.

carbamazepine: [p] enzyme induction.

cholestyramine: [p] reduces absorption of

anticoagulant.

glutethimide: [p] enzyme induction.

nafcillin: [ne] mechanism not established.

phenytoin: [ne] enzyme induction;

anticoagulant effect may increase transiently
at start of phenytoin therapy due to protein-
binding displacement.

primidone: [p] enzyme induction.

rifabutin: [p] enzyme induction.

rifampin: [p] enzyme induction.

3) effects of anticoagulants on other drugs:

hypoglycemics, oral: [p] dicumarol inhibits

hepatic metabolism of tolbutamide and
chlorpropamide.

phenytoin: [p] dicumarol inhibits metabolism

of phenytoin.
barbiturates: [p] increased antidepressant *inhibition of amine antidepressants,
metabolism. uptake into postganglionic tricyclic and
adrenergic neuron. heterocyclic
carbamazepine: [ne] enhanced metabolism
of antidepressants. *antimuscarinic effects
may be additive with other
cimetidine: [p] decreased antidepressant antimuscarinic drugs.
metabolism.
*metabolism inducible.
clonidine: [p] decreased clonidine
antihypertensive effect.
guanadrel: [p] decreased uptake of
guanadrel into sites of action. antidepressants,
tricyclic and
guanethidine: [p] decreased uptake of heterocyclic
guanethidine into sites of action. (cont'd)
monoamine oxidase inhibitors: [np] some
cases of excitation, hyperpyrexia, mania, and
convulsions, especially with serotonergic
antidepressants such as clomipramine and
imipramine, but many patients have received
combination without ill effects.

quinidine: [ne] decreased antidepressant

metabolism.

rifampin: [p] increased antidepressant

metabolism.

selective serotonin reuptake inhibitors

(ssris): [p]
*fluoxetine & paroxetine inhibit cyp2d6 &
decrease metabolism of antidepressants
metabolized by this enzyme (eg,
desipramine).

*citalopram, sertraline, and fluvoxamine are

only weak inhibitors of cyp2d6, but
fluvoxamine inhibits cyp1a2 and cyp3a4 and
thus can inhibit the metabolism of
antidepressants metabolized by these
enzymes (e.g. imipramine; nefazodone).

sympathomimetics: [p] increased pressor

response to norepinephrine, epinephrine,
and phenylephrine.
beta-adrenoceptor blockers: [p] increased *induction of hepatic barbiturates
β-blocker metabolism. microsomal drug-
metabolizing enzymes.
calcium channel blockers: [p] increased
calcium channel blocker metabolism. *additive cns depression
with other central nervous
cns depressants: [hp] additive central system depressants.
nervous system depression.

corticosteroids: [p] increased corticosteroid

metabolism.

cyclosporine: [ne] increased cyclosporine

metabolism.

delavirdine: [p] increased delavirdine

metabolism.
doxycycline: [p] increased doxycycline
metabolism.
barbiturates
estrogens: [p] increased estrogen (cont'd)
metabolism.

itraconazole: [p] increased itraconazole

metabolism.

ketoconazole: [p] increased ketoconazole

metabolism.

phenothiazines: [p] increased phenothiazine

metabolism.

quinidine: [p] increased quinidine

metabolism.

tacrolimus: [ne] increased tacrolimus

metabolism.

theophylline: [ne] increased theophylline

metabolism; reduced theophylline effect.

valproic acid: [p] decreased phenobarbital

metabolism.

see also anticoagulants, oral;

antidepressants, tricyclic.
1) drugs that may increase β-blocker effect: *beta-blockade beta-
(especially with adrenoceptor
cimetidine: [p] decreased metabolism of β- nonselective agents such blockers
blockers that are cleared primarily by the as propranolol) alters
liver, eg, propranolol. less effect (if any) on response to
those cleared by the kidneys, eg, atenolol, sympathomimetics with β-
nadolol. agonist activity (eg,
pinephrine).
furosemide: [p] decreased metabolism of
propranolol. *beta-blockers that
undergo extensive first-
hydralazine: [p] decreased metabolism of pass metabolism may be
propranolol. affected by drugs capable
of altering this process.
2) drugs that may decrease β-blocker effect:
*beta-blockers may
enzyme inducers: [p] barbiturates, reduce hepatic blood flow.
phenytoin, and rifampin may enhance β-
blockers metabolism; other enzyme inducers
may produce similar effects.

nonsteroidal anti-inflammatory drugs: [p]

indomethacin reduces antihypertensive
response; other prostaglandin inhibitors
probably also interact.

3) effects of β-blockers on other drugs: beta-

adrenoceptor
clonidine: [ne] hypertensive reaction if blockers
clonidine is withdrawn while patient is taking (cont'd)
propranolol.

insulin: [p] inhibition of glucose recovery

from hypoglycemia; inhibition of symptoms of
hypoglycemia (except sweating); increased
blood pressure during hypoglycemia.

lidocaine: [ne] decreased clearance of

intravenous lidocaine; increased plasma
lldocaine levels.

prazosin: [p] increased hypotensive

response to first dose of prazosin.

sympathomimetics: [p] increased pressor

response to epinephrine (and possibly other
sympathomimetics); this is more likely to
occur with nonspecific β-blockers.

acetaminophen: [ne] decreased *resins may bind with bile acid-

gastrointestinal absorption of orally administered drugs binding resins
acetaminophen. in gastrointestinal tract. e.g.
cholestyramine
digitalis glycosides: [ne] decreased *resins may bind in
gastrointestinal absorption of digitoxin gastrointestinal tract with
(possibly also digoxin). drugs that undergo
enterohepatic circulation,
furosemide: [p] decreased gastrointestinal even if the latter are given
absorption of furosemide. parenterally.

methotrexate: [ne] reduced gastrointestinal

absorption of methotrexate.

thiazide diuretics: [p] reduced

gastrointestinal absorption of thiazides.

thyroid hormones: [p] reduced thyroid

absorption.

see also anticoagulants, oral.

carbamazepine: [p] ↓ carbamazepine *verapamil, diltiazem, and calcium channel
metabolism with diltiazem & verapamil; perhaps nicardipine (but blockers (ccb)
possible ↑ in ccb metabolism. not nifedipine) inhibit
hepatic drug-metabolizing
cimetidine: [np] decreased metabolism of enzymes.
ccbs.
*metabolism of diltiazem,
cyclosporine: [p] decreased cyclosporine nifedipine, verapamil, and
metabolism with diltiazem, nicardipine, perhaps other calcium
verapamil. channel blockers subject
to induction and inhibition.
itraconazole: [p] decreased metabolism of calcium channel
ccbs. blockers (cont'd)

ketoconazole: [p] decreased metabolism of

ccbs.

phenytoin: [ne] increased metabolism of

ccbs.

rifampin: [p] increased metabolism of ccbs.

see also barbiturates, theophylline.

cimetidine: [p] decreased carbamazepine *induction of hepatic carbamazepine

metabolism. microsomal drug-
metabolizing enzymes.
clarithromycin: [p] decreased
carbamazepine metabolism. *susceptible to inhibition
of metabolism, primarily
corticosteroids: [p] increased corticosteroid by cyp3a4.
metabolism.

cyclosporine: [p] increased cyclosporine

metabolism.

danazol: [p] decreased carbamazepine

metabolism.

diltiazem: [p] decreased carbamazepine

metabolism.

doxycycline: [p] increased doxycycline

metabolism.

erythromycin: [ne] decreased

carbamazepine metabolism.

estrogens: [p] increased estrogen

metabolism.

haloperidol: [p] increased haloperidol

metabolism.

isoniazid: [p] decreased carbamazepine

metabolism.

itraconazole: [p] decreased metabolism of

carbamazepine.

ketoconazole: [p] decreased metabolism of

carbamazepine.

nefazodone: [ne] decreased carbamazepine

metabolism. carbamazepine
propoxyphene: [hp] decreased (cont'd)
carbamazepine metabolism.

selective serotonin reuptake inhibitors

(ssris): [ne] fluoxetine and fluvoxamine
decrease carbamazepine metabolism.

theophylline: [ne] increased theophylline

metabolism.

verapamil: [p] decreased carbamazepine

metabolism.

see also anticoagulants, oral;

antidepressants, tricyclic; calcium channel
blockers.
phenytoin: [p] decreased phenytoin *inhibits hepatic drug- chloramphenicol
metabolism. metabolizing enzymes.

sulfonylurea hypoglycemics: [p] decreased

sulfonylurea metabolism.
see also anticoagulants, oral.

benzodiazepines: [p] decreased metabolism *inhibits hepatic cimetidine

of alprazolam, chlordiazepoxide, diazepam, microsomal drug-
halazepam, prazepam, and clorazepate but metabolizing enzymes.
not oxazepam, lorazepam, or temazepam. (ranitidine, famotidine,
and nizatidine do not
carmustine: [ne] increased bone marrow appear to do so.)
suppression.
*may inhibit the renal
ketoconazole: [ne] decreased tubular secretion of weak
gastrointestinal absorption of ketoconazole bases.
due to increased ph in gut; other h2 blockers
and proton pump inhibitors would be *purportedly reduces
expected to have the same effect. hepatic blood flow, thus
reducing first-pass
itraconazole: [ne] decreased gastrointestinal metabolism of highly
absorption of itraconazole due to increased extracted drugs.
ph in gut; other h2-receptor antagonists and (however, the ability of
proton pump inhibitors would be expected to cimetidine to affect
have the same effect. hepatic blood flow has
been disputed.)
lidocaine: [p] decreased metabolism of
lidocaine; increased serum lidocaine.

phenytoin: [ne] decreased phenytoin

metabolism; increased serum phenytoin.

procainamide: [p] decreased renal excretion

of procainamide; increased serum
procainamide levels. similar effect with
ranitidine but smaller.
quinidine: [p] decreased metabolism of cimetidine
quinidine; increased serum quinidine levels. (cont'd)
theophylline: [p] decreased theophylline
metabolism; increased plasma theophylline.

see also anticoagulants, oral;

antidepressants, tricyclic; beta-adrenoceptor
blockers; calcium channel blockers,
carbamazepine.
amphotericin b: [ne] possible additive *metabolism inducible. cyclosporine
nephrotoxicity.
*susceptible to inhibition
androgens: [ne] increased serum of metabolism by cyp3a4.
cyclosporine. (tacrolimus and sirolimus
appear to have similar
barbiturates: [p] increased cyclosporine interactions.)
metabolism.

carbamazepine: [p] increased cyclosporine

metabolism.

clarithromycin: [p] decreased cyclosporine

metabolism.

diltiazem: [ne] decreased cyclosporine

metabolism.

erythromycin: [ne] decreased cyclosporine

metabolism.

fluconazole: [ne] decreased cyclosporine

metabolism, especially with large fluconazole
doses.

itraconazole: [p] decreased cyclosporine

metabolism.

ketoconazole: [ne] increased serum

cyclosporine with nephrotoxicity due to
decreased cyclosporine metabolism.

lovastatin: [ne] myopathy and

rhabdomyolysis noted in patients taking both
drugs.

nefazodone: [p] decreased cyclosporine

metabolism.

phenytoin: [ne] increased cyclosporine

metabolism.
cyclosporine
rifampin: [p] increased cyclosporine
metabolism. (cont'd)
ritonavir: [p] ↓ cyclosporine metabolism.

verapamil: [ne] ↓ cyclosporine metabolism.

see also barbiturates; calcium channel
blockers.
1) drugs that may increase digitalis effect: *digoxin susceptible to digitalis
amiodarone: [p] reduced renal digoxin inhibition of glycosides
excretion leads to increased plasma digoxin gastrointestinal
concentrations. absorption.

clarithromycin: [ne] reduced renal excretion *digitalis toxicity may be

of digoxin. increased by drug-
induced electrolyte
diltiazem: [p] increased plasma digoxin due imbalance (eg,
to reduced renal clearance. hypokalemia).

erythromycin: [ne] reduced renal excretion *digitoxin metabolism

of digoxin. inducible.

itraconazole: [ne] reduced renal excretion of *renal excretion of digoxin

digoxin. susceptible to inhibition.

potassium-depleting drugs: [p] increased

likelihood of digitalis toxicity.

propafenone: [p] increased plasma digoxin

levels.

quinidine: [hp] reduced digoxin excretion;

displacement of digoxin from tissue binding
sites; digitoxin may also be affected.

spironolactone: [ne] decreased renal

digoxin excretion and interference with some
serum digoxin assays.

verapamil: [p] increased plasma digoxin

levels.

2) drugs that may decrease digitalis effect:

kaolin-pectin: [p] decreased gastrointestinal
digoxin absorption.

penicillamine: [ne] decreased plasma

digoxin.

rifampin: [ne] increased metabolism of

digitoxin and possibly digoxin.

sulfasalazine: [ne] decreased

gastrointestinal digoxin absorption.
see also antacids; bile acid-binding resins.
benzodiazepines: [p] decreased metabolism *inhibits hepatic disulfiram
of chlordiazepoxide and diazepam but not microsomal drug-
lorazepam and oxazepam. metabolizing enzymes.

metronidazole: [ne] confusion and *inhibits aldehyde

psychoses reported in patients receiving this dehydrogenase.
combination; mechanisms unknown.

phenyloin: [p] decreased phenytoin

metabolism.

see also alcohol; anticoagulants, oral.

ampicillin: [np] interruption of enterohepatic *metabolism inducible. estrogens

circulation of estrogen; possible reduction in
oral contraceptive efficacy. other oral *enterohepatic circulation
antibiotics may have a similar effect. of estrogen may be
interrupted by alteration in
corticosteroids: [p] decreased metabolism bowel flora (eg, due to
of corticosteroids leading to increased antibiotics).
corticosteroid effect.

diazepam: [ne] decreased diazepam

metabolism.

griseofulvin: [ne] possible inhibition of oral

contraceptive efficacy; mechanism unknown.

phenytoin: [np] increased estrogen

metabolism; possible reduction in oral
contraceptive efficacy.

primidone: [np] increased estrogen

metabolism; possible reduction in oral
contraceptive efficacy.

rifabutin: [np] increased estrogen

metabolism; possible reduction in oral
contraceptive efficacy.

rifampin: [np] increased estrogen

metabolism; possible reduction in oral
contraceptive efficacy.

troglitazone: [np] increased estrogen

metabolism; possible reduction in oral
contraceptive efficacy.

see also barbiturates; carbamazepine.

clarithromycin: [p] decreased statin *lovastatin, simvastatin, hmg-coa
metabolism. and, to a lesser extent, reductase
atorvastatin are inhibitors
clofibrate: [np] increased risk of myopathy. susceptible to cyp3a4
inhibitors & inducers.
hmg-coa
diltiazem: [ne] decreased statin metabolism. *increased risk of additive
 myopathy risk with other reductase
cyclosporine: [p] decreased statin drugs that can cause inhibitors
metabolism. myopathy. (cont'd)
erythromycin: [p] decreased statin
metabolism

itraconazole: [p] decreased statin

metabolism.

ketoconazole: [p] decreased statin

metabolism.

nefazodone: [ne] decreased statin

metabolism.

methyldopa: [ne] decreased methyldopa binds with drugs in iron

absorption. gastrointestinal tract,
reducing absorption.
quinolones: [p] decreased absorption of
ciprofloxacin.

tetracyclines: [p] decreased absorption of

tetracyclines; decreased efficacy of iron.

thyroid hormones: [p] decreased thyroxine

absorption.
see also antacids.
clonidine: [ne] inhibits antiparkinsonism *levodopa degraded in levodopa
effect. gut prior to reaching sites
of absorption.
monoamine oxidase inhibitors: [p]
hypertensive reaction (carbidopa prevents *agents that alter
the interaction). gastrointestinal motility
may alter degree of
papaverine: [ne] inhibits antiparkinsonism intraluminal degradation.
effect.
*antiparkinsonism effect
phenothiazines: [p] inhibits of levodopa susceptible to
antiparkinsonism effect. inhibition by other drugs.

phenytoin: [ne] inhibits antiparkinsonism

effect.

pyridoxine: [p] inhibits antiparkinsonism

effect (carbidopa prevents the interaction).
see also antimuscarinics.
ace inhibitors: [ne] probable reduced renal *renal lithium excretion lithium
clearance of lithium; increased lithium effect. sensitive to changes in
sodium balance. (sodium
depletion tends to cause
diuretics (especially thiazides): [p] lithium retention.)
decreased excretion of lithium; furosemide *susceptible to drugs
may be less likely to produce this effect than enhancing central lithium (cont'd)
thiazide diuretics. nervous system lithium
toxicity.
haloperidol: [np] occasional cases of
neurotoxicity in manic patients, especially
with large doses of one or both drugs.

methyldopa: [ne] increased likelihood of

central nervous system lithium toxicity.

nonsteroidal anti-inflammatory drugs: [ne]

reduced renal lithium excretion (except
sulindac and salicylates).

theophylline: [p] increased renal excretion

of lithium; reduced lithium effect.
antidiabetic agents: [p] additive *increased monoamine
hypoglycemic effect. norepinephrine stored in oxidase
adrenergic neuron. inhibitors
buspirone: [ne] possible serotonin displacement of these (maois)
syndrome; avoid concurrent use. stores by other drugs may
produce acute
dextromethorphan: [ne] severe reactions hypertensive response.
(hyperpyrexia, coma, death) have been
reported. *maois have intrinsic
hypoglycemic activity
guanethidine: [p] reversal of the
hypotensive action of guanethidine.

mirtazapine: [ne] possible serotonin

syndrome; avoid concurrent use.

narcotic analgesics: [np] some patients

develop hypertension, rigidity, excitation;
meperidine may be more likely to interact
than morphine.

nefazodone: [ne] possible serotonin

syndrome; avoid concurrent use.

phenylephrine: [p] hypertensive episode,

since phenylephrine is metabolized by
monoamine oxidase.

selective serotonin reuptake inhibitors

(ssris): [p] fatalities have occurred due to
serotonin syndrome; ssris are
contraindicated in patients taking maois.
sibutramine: [ne] possible serotonin
syndrome; avoid concurrent use.

monoamine
sympathomimetics (indirect-acting): [hp] oxidase
hypertensive episode due to release of
inhibitors
stored norepinephrine (amphetamines,
ephedrine, phenylpropanolamine, (maois) (cont'd)
pseudoephedrine).

tramadol: [ne] possible serotonin syndrome;

avoid concurrent use.

venlafaxine: [ne] possible serotonin

syndrome; avoid concurrent use.
see also antidepressants, tricyclic and
heterocyclic; levodopa.
ace inhibitors: [p] decreased *prostaglandin inhibition nonsteroidal
antihypertensive response. may result in reduced anti-
renal sodium excretion, inflammatory
furosemide: [p] decreased diuretic, impaired resistance to drugs
natriuretic, and antihypertensive response to hypertensive stimuli, and
furosemide. reduced renal lithium
excretion.
hydralazine: [ne] decreased
antihypertensive response to hydralazine. *most nsaids inhibit
platelet function; may
methotrexate: [ne] possible increase in increase likelihood of
methotrexate toxicity (especially with bleeding due to other
anticancer doses of methotrexate). drugs that impair
hemostasis.
phenytoin: [p] decreased hepatic phenytoin
metabolism. *most nsaids are highly
bound to plasma proteins.
triamterene: [ne] decreased renal function
noted with triamterene plus indomethacin in *phenylbutazone may
both healthy subjects and patients. inhibit hepatic microsomal
drug metabolism (also
see also anticoagulants, oral; beta- seems to act as enzyme
adrenoceptor blockers; lithium. inducer in some cases).

*phenylbutazone may
alter renal excretion of
some drugs.
1)drugs whose metabolism is stimulated by *induces hepatic phenytoin
phenytoin: microsomal drug
metabolism.
corticosteroids: [p] decreased serum
corticosteroid levels. *susceptible to inhibition
of metabolism by cyp2c9
doxycycline: [p] decreased serum and, to a lesser extent,
doxycycline levels. cyp2c19.

methadone: [p] decreased serum

methadone levels; withdrawal symptoms.

mexiletine: [ne] decreased serum mexiletine

levels.

quinidine: [p] decreased serum quinidine phenytoin

levels. (cont'd)

theophylline: [ne] decreased serum

theophylline levels.

verapamil: [ne] decreased serum verapamil

levels.
see also cyclosporine, estrogens.

2) drugs that inhibit phenytoin metabolism:

amiodarone: [p] increased serum phenytoin;
possible reduction in serum amiodarone.

chloramphenicol: [p] increased serum

phenytoin.

felbamate: [p] increased serum phenytoin.

fluconazole: [p] increased serum phenytoin.

fluoxetine: [p] increased serum phenytoin.

isoniazid: [np] increased serum phenytoin;

problem primarily with slow acetylators of
isoniazid.

miconazole: [p] increased serum phenytoin.

ticlopidine: [np] increased serum phenytoin.

see also cimetidine; disulfiram;
phenylbutazone.

3)drugs that enhance phenytoin metabolism:

rifampin: [p] decreased serum phenytoin
levels.
clarithromycin: [ne] decreased pimozide *susceptible to cyp3a4 pimozide
metabolism. inhibitors; may exhibit
additive effects with other
erythromycin: [ne] decreased pimozide agents that prolong qtc
metabolism interval.

itraconazole: [ne] decreased pimozide

metabolism.

ketoconazole: [ne] decreased pimozide

metabolism.

nefazodone: [ne] decreased pimozide

metabolism.

ace inhibitors: [ne] additive hyperkalemic *additive effects with potassium-

effect. other agents increasing sparing diuretics
serum potassium (amiloride,
potassium supplements: [p] additive concentration. spironolactone,
hyperkalemic effect; especially a problem in
triamterene)
presence of renal impairment. *may alter renal excretion
of substances other than
see also digitalis glycosides; nonsteroidal potassium (eg, digoxin,
anti-inflammatory drugs. hydrogen ions).
clofibrate: [p] reduced glucuronide *interference with renal probenecid
conjugation of clofibric acid. excretion of drugs that
undergo active tubular
methotrexate: [p] decreased renal secretion, especially weak
methotrexate excretion; possible acids.
methotrexate toxicity.
*inhibition of glucuronide
penicillin: [p] decreased renal penicillin conjugation of other
excretion. drugs.

salicylates: [p] decreased uricosuric effect of

probenecid (interaction unlikely with less than
1.5 g of salicylate daily).
acetazolamide: [p] decreased renal *metabolism inducible. quinidine
quinidine excretion due to increased urinary inhibits cyp2d6.
ph; elevated serum quinidine.
*renal excretion
amiodarone: [ne] increased serum quinidine susceptible to changes in
levels; mechanism not established. urine ph.

kaolin-pectin: [ne] decreased

gastrointestinal absorption of quinidine.

rifampin: [p] increased hepatic quinidine

metabolism.

see also anticoagulants, oral;

antidepressants, tricyclic; barbiturates;
cimetidine; digitalis glycosides; phenytoin.

caffeine: [p] ciprofloxacin, enoxacin, and, to *susceptible to inhibition quinolone

a lesser extent, norfloxacin, inhibit caffeine of gastrointestinal antibiotics
metabolism. absorption.
sucralfate: [hp] reduced gastrointestinal *some quinolones inhibit
absorption of ciprofloxacin, norfloxacin, and hepatic microsomal drug-
probably other quinolones. metabolizing enzymes.

theophylline: [p] ciprofloxacin, enoxacin,

and, to a lesser extent, norfloxacin inhibit
theophylline metabolism; levofloxacin,
lomefloxacin, ofloxacin, and sparfloxacin
appear to have little effect.

see also antacids; anticoagulants, oral.

corticosteroids: [p] increased corticosteroid induction of hepatic rifampin
hepatic metabolism; reduced corticosteroid microsomal drug-
effect. metabolizing enzymes.

itraconazole: [p] increased itraconazole

metabolism; reduced itraconazole effect.

ketoconazole: [ne] increased ketoconazole

metabolism; reduced ketoconazole effect.

mexiletine: [ne] increased mexiletine

metabolism; reduced mexiletine effect.

sultonylurea hypoglycemics: [p] increased

hepatic metabolism of tolbutamide and
probably other sulfonylureas metabolized by
the liver (including chlorpropamide).

theophylline: [p] increased theophylline

metabolism; reduced theophylline effect.

see also anticoagulants, oral; beta-

adrenoceptor blockers; calcium channel
blockers; cyclosporine; digitalis glycosides;
estrogens.
carbonic anhydrase inhibitors: [ne] *interference with renal salicylates
increased acetazolamide serum excretion of drugs that
concentrations; increased salicylate toxicity undergo active tubular
due to decreased blood ph. secretion.

corticosteroids: [p] increased salicylate *salicylate renal excretion

elimination; possible additive toxic effect on dependent on urinary ph
gastric mucosa. when large doses of
salicylate used.
heparin: [ne] increased bleeding tendency
with aspirin, but probably not with other *aspirin (but not other
salicylates. salicylates) interferes with
platelet function.
methotrexate: [p] decreased renal
methotrexate clearance; increased *large doses of salicylates
methotrexate toxicity (primarily at anticancer have intrinsic
doses). hypoglycemic activity.

sulfinpyrazone: [hp] decreased uricosuric *salicylates may displace

effect of sulfinpyrazone (interaction unlikely drugs from plasma protein
with less than 1.5 g of salicylate daily). binding sites.

see also antacids; anticoagulants, oral;

probenecid.
benzodiazepines: [ne] inhibition of *susceptible to inhibition theophylline
benzodiazepine sedation. of hepatic metabolism by
cyp1a2.
dlltlazem: [p] decreased theophylline
metabolism by cyp1a3. *metabolism inducible.
theophylline
clarithromycin: [ne] decreased theophylline
metabolism. (cont'd)

erythromycin: [p] decreased theophylline

metabolism.

fluvoxamine: [p] decreased theophylline

metabolism.

smoking: [hp] increased theophylline

metabolism.

tacrine: [p] decreased theophylline

metabolism.

ticlopidine: [ne] decreased theophylline

metabolism.

verapamil: [p] decreased theophylline

metabolism.

zileuton: [p] decreased theophylline

metabolism.

see also barbiturates; carbamazepine;

cimetidine; lithium; phenytoin; quinolones;
rifampin.

summary

learning objectives

•distinguish between pharmacokinetic and pharmacodynamic drug

interactions
•identify common and clinically significant drug interactions
•formulate appropriate alternative treatment regimens minimizing the
potential for drug interactions

outline

•general background
•define various pharmacokinetic drug interactions
•define various pharmacodynamic drug interactions
•explore some common and clinically significant drug interactions
•discuss patient cases

background

•drug interactions can be a significant cause of medication errors,

adverse medication reactions, and patient morbidity and mortality
•legal ramifications possible
•however not all drug interactions are “bad”
•synergy
•altered metabolism or elimination
•two main categories of drug interactions
•pharmacokinetic
•pharmacodynamic
•other types of drug interactions can occur such as physical or
chemical incompatibilities
•drug interactions can occur with
•other drugs
•herbs/ dietary supplements
•foods or beverages (especially grapefruit juice or alcohol)
•smoking
types of drug interactions
•pharmacokinetic
127absorption: common with di/trivalent metals and enteral feeds
128distribution
129metabolism: most common type of pharmacokinetic drug-drug
interaction; cp450 isoenzymes – substrate vs inducer vs inhibitor
130excretion

•pharmacodynamic
•substance a enhances or duplicates the intended effect or adverse
effect of substance b i.e. agonist
•substance a acts antagonistically with substance b

pharmacokinetic drug interactions

i) absorption
•product a binds with product b in the gi tract
•example cholestyramine
•most common example is chelation of agents with di/trivalent metals
•examples ca, al, zn, mg, multivitamins, antacids, etc. chelate
products such as antibiotics in the quinolone or tetracycline
family
•result = decreased effectiveness of both agents
•management= separate doses (1 hour before or 2 hours after)

ii) distribution
•least common type of pharmacokinetic interaction
•drug-drug interactions of this type are quite rare
•drug-disease state interactions more common
•if a drug is particularly hydro or lipophillic, then patients with certain
disease states (chf, crf, obesity) may react differently

iii) metabolism
•most common type of pharmacokinetic drug interaction
•hepatic enzymes – cytochrome p 450 system metabolizes
numerous drugs
•many different isoenzymes
•3a4, 2d6, 1a2, 2c9, and 2c19 most common
•3a4 most clinically significant
•many drugs induce or inhibit certain hepatic enzymes
•many drugs are substrates of the cp 450 system
•drugs that induce this system decrease the concentrations of other
drugs metabolized by cp 450 (results in decreased therapeutic
effects)
•drugs that inhibit cp450 enzymes cause increases in the
concentrations of other drugs metabolized by cp450 (may increase
risk of adverse effects)
•note that other substances (foods like grapefruit, herbs like st. john’s
wort, and smoking) can also affect cp 450
• cp 450 3a4 isoenzyme most common
•common 3a4 inducers
•carbamazepine
•phenobarbital
•phenytoin
•rifampin

•common 3a4 inhibitors

•amiodarone
•cannabinoids
•erythromycin and clarithromcyin
•azole antifungals
•fluvoxamine, fluoxetine, nefazodone, sertraline, others possible
•protease inhibitors
•grapefruit

iv) excretion
•less common than metabolism or absorption
•substance a may alter the renal (or other types of) elimination of
substance b
•example
•probenecid competitively inhibits renal tubular excretion of many
agents, resulting in reduced clearance of penicillins, cephalosporins,
benzodiazepines, sulfonylureas, others

pharmacodynamic drug interactions

i) synergistic, additive, or agonist effects

•two (or more) products may have similar mechanisms of action
(moas), desired treatment outcomes, or adverse effect profiles
•examples
•lovastatin + clofibrate = decreased lipid and triglyceride profiles and
increased risk of myopathy or rhabdomyolysis
•acetyl salicylic acid (asa) + ginkgo biloba = increased risk of
bleeding (both agents have antiplatelet effects)

ii) antagonism
•opposing moas, desired treatment outcomes, or adverse effect
profiles
•one foot on the brake, one on the gas
•examples
•bethanechol (cholinergic agent) and ipratropium (anticholinergic
agent)
•heparin and protamine
•albuterol and atenolol

common, clinically significant drug interactions

•antidepressants
•anticonvulsants
•cisapride (reverted to “investigational” drug)
•digoxin
•estrogens and oral contraceptives
•statins
•warfarin
•non-prescription medications

antidepressants
•antidepressants are used by a huge portion of the population

•drug interaction potential varies greatly

•although many antidepressants affect cp 450 (inhibition), different

isoenzymes are affected to a different degree

•predict and prevent drug interactions

•many cp 450 interactions possible

•relative ranking of newer antidepressants based on cp 450 drug
interaction potential:
•most likely to interact:
•fluvoxamine, fluoxetine, paroxetine, nefazodone
•less likely to interact
•sertraline

•least likely to interact

•mirtazapine, venlafaxine, citalopram

•use caution combining multiple agents that affect serotonin,

potential result = serotonin syndrome
•other antidepressants
•triptan migraine treatments
•zyban

•maois uncommonly used, but commonly interact

•2 week washout

anticonvulsants
•significant drug interactions frequently occur with anticonvulsants
•anticonvulsants are often used in combination, even though
they may interact with each other
•examples: phenytoin, phenobarb, valproic acid (va), carbamazepine
•not necessarily a contraindication
•monitor serum drug levels and signs & symptoms (s/sx) of adverse
effects

i) carbamazepine
•carbamazepine can decrease the effectiveness of:
•oral contraceptives
•cyclosporine
•phenytoin
•benzodiazepines
•valproic acid
•thyroid preparations
•warfarin
•others

•these meds can increase the concentrations and adverse effects of

carbamazepine:
•erythromycin
•inh
•propoxyphene
•verapamil & diltiazem
•cimetidine (not other h2s)

ii) phenytoin
•phenytoin may decrease the effectiveness of:
•ocs, itraconazole, mebendazole, midazolam, va, cyclosprine,
theophylline, doxycycline, quinidine, disopyramide, carbamazepine
•phenytoin’s effectiveness may be decreased by:
•rifampin, folic acid, theophylline, antacids, sulcralfate, and some
chemo
• continuous enteral feedings as feeds bind to phenytoin, drastically
decreasing absorption

•agents which may increase phenytoin conc/toxicity:

•inh, fluconazole, ticlopidine, amiodarone, cimetidine, disulfiram,
fluoxetine, sulfonamides

•phenytoin may increase the toxicity of these agents:

•warfarin, dopamine, barbiturates,
•valproic acid may either increase or decrease phenytoin
concentrations

iii) valproic acid (va)

•agents that may decrease va concentrations:
•carbamazepine, cholestyramine, lamotrigine

•va may decrease concentrations/effects of:

•phenytoin

•agents that may increase va concentrations:

•cimetidine, erythromycin, salicylates (asa)

•va may increase concentrations/effects of:

•tricyclic antidepressants (tcas)

digoxin
•digoxin (dig)
•many clinically significant drug interactions
•variety of mechanisms
•if combinations unavoidable, increase monitoring of serum digoxin
levels and clinical s/sx of adverse effects

•“normal” dig levels typically range from 0.8 to 2.5 ng/ml depending
on laboratory and disease state

•remember that adverse effects to dig can occur when serum levels
are within the “normal” range

•agents that may decrease digoxin levels

•phenytoin
•cholestyramine (and other bile acid sequestrants)
•neomycin
•others

•agents that may increase digoxin levels

•amiodarone
•propafenone
•quinidine
•verapamil
•itraconazole
•calcium preparations
•cyclosporin
•erythromycin & clarithromycin
•tetracycline (tcn)
•others

estrogens and oral contraceptives (ocs)

•combining estrogens or ocs with the following agents may result in
breakthrough bleeding or decreased effectiveness
•carbamaxepine
•barbiturates
•phenytoin
•rifampin
•tcn, ampicillin and potentially other antibiotics

•estrogens with corticosteroids may increase steroid toxicity

statins
•most hmg co a reductase inhibitors are significantly metabolized by
be the cp450 3a4 isoenzyme and most interactions are related to 3a4
enzyme inhibition

•in addition to metabolism interactions with statins, monitor also for

myopathy “synergy” and liver function tests (lft) elevations

•agents commonly interacting with statins include

•erythromycin or clarithromycin (not azithromycin)
•azole antifungals
•protease inhibitors
•some ssris including fluvoxamine, fluoxetine, sertraline, etc.
•
•note that pravastatin has fewer cp 450 3a4 interactions and may
be preferable over other statins if trying to avoid a specific drug
interaction
•pravastatin is no less likely to interact with other drugs causing
myopathies or increased lfts

warfarin
•the king of drug interactions

•drug-drug, drug-food, and drug-herb interactions are very common

•narrow therapeutic window

•very serious consequences

•decreased effectiveness may result in thrombosis
•increased risk of adverse effects, especially bleeding
•diet needs to be consistent

•foods high in vitamin k

•green vegetables
•mayonnaise
•oils (canola & soybean)

•can still eat these foods, just keep similar amount in diet

•drugs that may decrease warfarin’s anticoagulant effects:

(procoagulants)
•estrogens/ ocs
•vitamin k (mvis)

(decreased absorption)
•aluminum hydroxide
•cholestyramine et al

(enzyme induction)
•barbiturates
•carbamazepine
•griseofulvin
•phenytoin
•nafcillin
•rifampin

•drugs that increase bleeding tendency

(inhibit procoagulant factors)
•antimetabolites
•quinidine
•quinine
•salicylates

(ulcerogenic drugs)
•corticosteroids
•nsaids and cox 2s to a lesser extent

•enhanced anticoagulant effects

•other anticoagulants, antiplatelets, thrombolytics
•altered metabolism, etc.
•alcohol
•antimicrobials including quinolones, smz-tmp, erythromycin, -azole
antifungals, metronidazole
•phenytoin
•disulfiram
•cimetidine
•others

•many herbal products and dietary supplements can also interact

with warfarin
•remember the “four gs”
•feverfew
•ginkgo biloba
•ginseng
•garlic
•ginger

•many others possible, including st. john’s wort

non-prescription drug interactions

•cimetidine has many drug interactions
•note other h2 antagonists are safer options

•cough/cold medications – watch blood pressure

•asa & other nsaids

•antacids- watch chelation drug interactions

•herbal products – so little is known about their safety when

combined with prescription drugs
age as a consideration in drug therapy
1
1) many factors can alter a patient’s responses to drugs, and
sometimes you can do something about them to help normalize the
drug response. one that you can’t do anything about is their age.

1 this handout highlights some of the major age-related factors you

should consider during your clinical experiences. the emphasis is on
pharmacokinetics, since changes in the way an individual absorbs,
distributes, metabolizes, and excretes drugs are among the key
factors that affects drug responses.

2 there are some data presented in this handout: some key facts and
concepts that you need to know. however, a major purpose of these
notes is simply to get you thinking about the ages of your patients
ahead of time.

3that’s so that when you get more detailed information about specific
drugs you might have a better idea of how to prescribe them and
monitor their effects — hopefully to optimize therapy and minimize
problems as best as possible. you’ll be better able to anticipate how
things might change or need to be changed.

4you should also come away with the concept that although small
children and older adults are “more sensitive” to the effects of many
drugs — and therefore need smaller doses of drugs than a young
adult, there are exceptions.
5importantly, for drugs overall there is no precise relationship
between the patient’s age and the dose of a drug that is “right.”
we’ll look at the extremes of the life-span: first, briefly, infants,
neonates, and children; and then we’ll summarize some key points
about the elderly.

pediatric patients
1immaturity of the many processes that affect drug
pharmacokinetics, and the subsequent changes of them with
maturation, affects drug responses in pediatric patients.

2although it varies with the text you consult, you’ll usually find that
there are four main age groups that comprise the pediatric
population (excluding preterm infants):
a) term to 4 weeks old (neonates)
b) 1 month to 2 years old (infants)
c) 2 to 12 years old (children)
d) 12 to 18 years old (however, many drugs approved for use in
adults are approved for “children” at least 12 years old)

1for the purpose of this discussion, maturation can be defined as

the process(es) of acquiring functional (and structural)
characteristics similar to those of the “typical adult.”

2obviously, the body doesn’t mature in increments. it is, instead, a

continuous process that can vary in speed depending on the
intrinsic make-up of the individual, and on many external factors
too. various aspects of maturation continue through puberty.

3before we look at characteristics of various age groups,

particularly in the context of pharmacokinetics and maturation
of pharmacokinetic processes, you might wonder when some of
these processes reach the “adult” stage. table 1 gives some
insight. you should see that, on average, most of the major
determinants of pharmacokinetics reach adult levels by one
year of age.
table 1. approximate ages at which selected determinants of
pharmacokinetics reach “adult levels”
3 months gastric acid secretion
 (gastric ph)
6 – 8 months gastric emptying time
overall, about 1 year;
5 months - 5 years for some
phase i reactions; hepatic metabolism
3 – 6 months
for many phase ii reactions
overall, about 1 year;
3 – 5 months to attain mature renal function
gfr;
6 – 9 months for tubular
secretion to mature;
1 year for adult-level renal blood
flows

i) neonates
1variable drug actions occur in neonates because of the biologic
characteristics of newborns, including:
a. small body mass
b. low body fat content
c. high body water volume
d. greater permeability of many membranes, including those
of the skin and the blood-brain barrier.

 the physiologic instability of premature infants also

requires special considerations in drug therapy.
[for the purpose of this discussion, neonates are children in or
younger than their first four postnatal weeks. we will not consider
premature infants (< 36 weeks gestational age)]

absorption
1in newborns, prolonged gastric transit time, variable gastric ph and
enzyme function, and the absence of intestinal flora, all affect the
absorption of drugs that are given orally.

1low peripheral perfusion rates and immature heat regulating

mechanisms may also interfere with absorption.

2topical medications are absorbed more quickly, and usually more

completely, through the newborn’s relatively thin cutaneous barrier
such that the risk of toxicity is greater.

3drug absorption can also occur through the placenta, and therefore
newborns should be evaluated for drug effects whenever the mother
has received any medication.

4it’s fairly common knowledge that maternal use of alcohol and

nicotine, and misuse of a variety of legal or illegal drugs (e.g.,
cocaine, heroin) can cause a host of problems in the newborn.

5however, many drugs prescribed by a physician (properly or not)

can cause problems in the neonate, regardless of whether they were
used short-term or for some longer period during pregnancy.

6drugs given to the mother for pain control or regulation of labor can
pass to the fetus during labor. in addition, drugs prescribed for the
mother as part of her own long-term or perinatal care can be
absorbed in utero and affect the newborn.

7perhaps highest on the list are anticonvulsant drugs, many of the

oral hypoglycemic drugs used to manage diabetes mellitus (insulin
should be used instead of them when pharmacologic control of
diabetes is necessary during pregnancy), some antihypertensive
drugs, and several antibiotics and anticancer agents.

distribution
1newborns have a low concentration of plasma proteins and a
diminished binding capacity of albumin. this results in an overall
decreased total plasma protein binding capacity with respect to drugs
that are extensively plasma protein-bound.

1this decreased binding capacity can be responsible for some serious

adverse drug effects. for example, plasma proteins can bind bilirubin.
drugs that are highly protein-bound can displace the bilirubin and so
may lead to brain damage from kernicterus as a result of
hyperbilirubinemia. sulfonamide antibiotics are a prime example of
this.

2in addition, immature glial development, especially evident among

premature infants, permits greater permeability of the blood-brain
barrier, allowing both drugs and bilirubin rapid and more complete
access to the central nervous system, leading to a heightened risk of
adverse effects.

3the volume of distribution within neonatal body compartments differs

greatly from the adult. total body water content amounts to 70% to
80% of body weight in premature and newborn infants, compared
with adult values of about 50% to 55%. extracellular fluid is about
40% of total body weight — roughly twice the adult value.

4the increased body water content, coupled with the low plasma
protein binding capacity of the neonate, result in an expanded volume
of distribution for water-soluble drugs. a larger relative dose of such
drugs may be necessary to produce the desired therapeutic effect(s).

5conversely, the lower level of body fat in neonates may necessitate

lower relative doses of lipid-soluble drugs, a portion of which
otherwise would accumulate in lipid depots and temporarily be unable
to cause effects.

metabolism
1in general, hepatic drug-metabolizing enzymes are immature in the
newborn and are especially ineffective in the premature neonate.
after birth, metabolic capacity may rise dramatically from a low of
about one-fifth to one-third the adult rate during the first weeks of life,
to more than double the adult rate at three years of age.

1because of their poor drug metabolizing capabilities, newborn

infants are at high risk for drug toxicity; therefore, drug dosages need
to be determined carefully. (there are exceptions to this, as noted
below in a brief discussion of theophylline, a bronchodilator drug
that’s widely used for managing asthma in children.)

2neonates also produce different metabolic products for some drugs

than do adults, suggesting that different metabolic pathways may be
present or at least predominant during maturation. unique metabolites
have been found in newborns for several drugs, including
chlorpromazine (an antipsychotic drug) & theophylline.
 excretion

1renal function is, overall, poorly developed in neonates. as a result,

neonates excrete drugs more slowly.

1newborns have a diminished ability to concentrate urine; and a

lower urine ph, which also affects excretion of some compounds.

2renal function overall approaches adult levels at the end or the first
year of life. however, as noted in table 1 above, some aspects or
determinants of renal excretory function reach adult levels somewhat
earlier.

ii) infants and children

1several physiologic factors influence drug administration to infants (5

– 52 weeks postnatal) and children (1 –12 years of age). progressive
biologic maturity and growth stabilize the body’s responses to drugs
until those drug responses eventually approximate those of the adult.

1as a child grows older there is an increase in body mass, a

difference in body fat content, and a decrease in body water volume,
all of which can influence drug absorption, distribution, metabolism,
and excretion.

2in addition, anatomic barriers such as the skin and the blood-brain
barrier become more effective as the infant matures. rapid growth
spurts during childhood and puberty may also affect drug response.

3table 2, on the next page, summarizes some of the traits of infants

and very young children.

table 2. summary: some physiologic characteristics of infants, and

their pharmacokinetic consequences
consequence characteristic
expanded volume of distribution, diminished blood high total body water content
levels, of water-soluble drugs
increased blood levels of highly lipid-soluble drugs low body fat

enhanced topical absorption of drugs, toxins; increased membrane

enhanced cns effects of lipid-soluble drugs permeability, especially of
skin, blood-brain barrier
more complete and/or faster absorption of drugs that relatively lower gastric acid-
are completely or partially inactivated by gastric acid, secreting capacity
or drugs that are mainly ionized at low ph

may dehydrate quickly, thereby elevating concentration immature body temperature

of drug in blood, other aqueous fluid compartments regulation

delayed excretion or metabolism of certain drugs immature renal or hepatic

(longer half-life) function

--------------------
absorption
1gastric acidity does not begin to approach adult values until about
two to three months of age. this early relative lack of gastric acid
contributes to exaggerated absorption of some drugs so that, for
example, oral benzyl penicillin (which at older ages is inactivated by
gastric acid) is well absorbed in infants.

1gastric emptying rates reach adult levels at about 6 to 8 months.

2barriers such as the skin and the blood-brain barrier become more
effective as the infant grows, making the child somewhat less
vulnerable to toxic effects of some drugs.

distribution
1protein binding of drugs generally reaches adult levels by one year
of age. before then, the relatively diminished levels of plasma
proteins, coupled with a lower binding capacity of those proteins for
many drugs, has clinical implications for drugs that normally tend to
be normally extensively bound.

1recall that drug molecules, while they are bound to plasma proteins,
are pharmacologically inactive (and are also unable to be excreted or
metabolized). thus, for a given total level (or concentration) of drug in
the blood, a greater fraction will be unbound, and so there exists the
potential for greater (if not excessive or toxic) effects.
2children also have a relatively higher total body water content until
about two years of age. thus, to account for a greater volume of
distribution of water-soluble drugs, children younger than that age
may require larger doses than older children.

3given the presence of both diminished plasma protein levels and

protein binding capacity (which could warrant reduced doses of highly
bound drugs), and a higher body water content (which could
necessitate reduced dosages), extra care in dosing and monitoring
are important.

metabolism
1metabolic rates in infants and children up to about two to three years
of age are, in general, higher than adult values. they decline to adult
rates by puberty. therapeutic drug dosages relative to body weight
may be greater for children than for adults.

1an important example is theophylline. its dose should be

individualized for each child based on body weight, with further
dosage adjustments to account for individual metabolic variations.
this is done, in part, bynmonitoring the child’s plasma concentrations
of the drug. as the child matures, hepatic enzymes may change such
that the clearance of theophylline will be reduced, and further dosage
adjustments probably will be needed.

excretion
1mature renal and hepatic function is not reached until about six to 12
months of age.

1until then, repeat doses of drugs should be given cautiously.

2dosages of drugs excreted largely unchanged (unmetabolized) by

the kidneys, such as digoxin (for congestive heart failure) and
gentamicin (an aminoglycoside antibiotic).

dosage adjustments
1the package inserts and other “prescriber information” sources for
many drugs — particularly drugs that are used extensively in
pediatrics — will list pediatric dosage guidelines. you should always
check written guidelines before deciding on a dose; indeed, you
should always check an authoritative source to see whether a drug
should be prescribed for a child at all, since some medications are
not approved for use in patients younger than a certain age.

1sometimes you may have to estimate pediatric dosages:

1.some recommended adjustments are quite general (e.g., they will
list recommended dosages for a rather wide range of ages).
2.the adjustments may be based solely on age, or on body weight in
addition to age. but in every case they are nothing more than
recommended starting points.
3.if there are impairments in drug distribution or (more likely) in
disposition (metabolism and/or excretion) or due to drug-drug
interactions, further adjustments will be needed, depending on the
drug.

2there are several formulas that can be used to extrapolate a

pediatric dose from the usual adult dose.
1. one formula is based on body surface area:
child’s dose = body surface area (m 2) x (adult dose)
1.7
2. other formulae are based on the child’s age or weight,
such as:
fried’s rule (for children 1 year old or younger):
child’s dose = age in months x (adult dose)
150 months

clark’s rule (for children 2 years old or younger):

child’s dose = weight in pounds x (adult dose)
150 pounds

young’s rule (for children 2 years old or older):

child’s dose = age in years x (adult dose)
(age in years + 12)

(the above formulae are for information only. you should be aware of
their existence, but you do not need to memorize the formulae).
pediatrics text books (and pediatric therapeutics books in particular)
also usually contain a nomogram that allows better estimation of
pediatric doses that take into account the child’s weight, body surface
area, and height.
drug responses in children may differ qualitatively, as well as
quantitatively
1it’s a common and usually correct assumption that children are
“more sensitive” than a young adult to the effects of most drugs,
mainly because of pharmacokinetic differences.

1an adult dose generally is simply too big: the effects of too much
drug given to a child are qualitatively similar to those in an adult, only
of greater magnitude.

2nonetheless, some drugs can cause effects (and usually they are
adverse effects) that are qualitatively different from those in adults...
adverse responses that are relatively unique to children. some of
them are summarized in the following table.

table 3. some adverse drug responses that are “unique” to the fetus,
neonates, or children
adverse effect drug
when administered to pregnant women, angiotensin converting enzyme
may cause fatal underdevelopment of (ace) inhibitors (e.g., captopril; used
fetal renal system (kidneys, etc.) mainly for hypertension or
congestive heart failure)
reye syndrome if given to some aspirin, other salicylates
children with influenza, chickenpox,
other viral illnesses

gray syndrome when given to mother in chloramphenicol (antibiotic)

utero or to neonates, infants.

linear growth suppression with glucocorticosteroids (anti-

prolonged systemic administration inflammatory drugs, very effective
for asthma, etc.)

brain damage hexachlorophene (topical

disinfectant)
gingival hyperplasia phenytoin (anticonvulsant)

kernicterus in neonates sulfonamides (antibiotics)

staining of developing teeth (in utero on tetracyclines (antibiotics)

through development of permanent
teeth)
drug misuse in children
parents or guardians are most often responsible for administering
medication to infants and young children.
management of drug therapy requires attention, coordination (who is
responsible for giving medications to the child? who’s turn is it
today?), and some understanding of the drug(s) to be given (when to
give them; how; and so on).

in many cases, young or poorly educated parents do not have the

experience or knowledge to ask appropriate questions about a drug
in order to clarify their understanding of the administration
instructions.

common causes of drug misuse in pediatric patients include the

following. a major way to reduce the risk and incidence of these
problems is education. parents or other caregivers should be given
precise and, preferably, written instructions about medicating their
children. they should always be encouraged to contact a health care
provider if they have questions.
1. multiple medication dispensers (e.g., mother, father, grandmother,
babysitter), resulting in the risk of duplicated or missed doses.

2. use of incorrect prescriptions (e.g., from previous illnesses or from

another child with similar symptoms).

3. discontinuance of medication as soon as symptoms appear to be

alleviated (particularly problematic with antibiotic and anticonvulsant
therapy).

4. supplementing more than one medication without the doctor’s

knowledge or supervision.

5. accidental ingestion of medications (medications are a common

source of poisoning in childhood).

6. baby’s ingestion of drug through mother’s breast milk. (it is

important for the prescriber to be aware of drugs that are excreted in
breast milk, and to advise the mother accordingly as to whether to
avoid breast-feeding or stop taking the drug.) most drug references
(and package inserts for all drugs) have information/advice about
what to do.

7. measurement errors, mainly with liquid dosage forms. there is

considerable misunderstanding of terms such as what a “teaspoonful”
means, or what a household teaspoon contains. it’s assumed to be 5
ml, but spoons vary in size and capacity, and in some cases even
slight errors of measurement can cause problems, whether
immediately or after several doses have been given.
when measuring is critical, advise the caregiver that very
inexpensive, well calibrated syringes for measuring and administering
liquids are available at virtually every pharmacy.

8. spitting or spilling medication by a resistant child, leaving parents

or other caregivers uncertain about how much drug was actually
ingested by the child. one assumption is that the child got little, if any
of the drug, and so the response is to give another dose. conversely,
one might assume that the child consumed the entire dose, when, in
fact, little was ingested. as a result, the child is underdosed.

9. inability to assess accurately side effects that might be developing

in a child as a result of drugs.
this is complicated by a child’s lack of or poorly developed language
and his or her inability to otherwise recognize, understand, and
communicate symptoms or signs of drug-induced problems.
10. the belief — equally applied to adult patients — that “if a small
dose is good, more is better.”

can the “right” dose for a child be larger than the right dose for
an adult?

1as surprising as it may seem, in a few (but important) instances the

answer to this question is yes.
2listed below are maximum oral daily maintenance doses for
anhydrous theophylline, which is classified as a methylxanthine
bronchodilator:
3at one time this drug was one of the most widely used oral
 bronchodilators for asthma patients of all ages. according to
pulmonologist experts theophylline now ranks as a third- or fourth-
line maintenance drug, especially for adults.

2its margin of safety (the difference between average effective and

average toxic blood concentrations is small.

3however, for various reasons it is still widely used, especially in

pediatrics (for which asthma is still the most common cause of
hospital admissions, morbidity, and mortality).

4look at the data and notice how the general rule “children get
smaller drug doses than adults” doesn’t apply.

table 4. typical oral maximum daily maintenance

doses of anhydrous theophylline,
a bronchodilator, at various ages*
dose per 24 hr, mg/kg age
13 adults, children > 16 years
18 12 – 16 years
20 9 – 12 years
24 6 months – 9 years
4-12 infants (= < 6 months)
* the doses listed as “per 24 hours” are given in divided doses at
specified intervals throughout the period. further adjustments must be
made based on other characteristics of the individual patient.

the average adult weighs 70 kg, so 13 mg/kg x 70 kg = 910 mg, or

roughly 900 mg per day. but what would happen if you remembered
that theophylline daily dosages for, say, your 6 month- to 9 year-old
patient was “bigger than” the daily dose for an adult , but you forgot
that “bigger than” only applied when you normalize the dose to the
patient’s body weight? that is, what if you gave your 6 month- to 9
year-old patient more than 900 mg/day, instead of more than 13
mg/kg per day?

older adults
1over the last 100 years the number of elderly people (age 65 and
older) in our society has grown faster than the rest of the population.

1one ramification of this “graying” of society is a rapid increase in the

needs and demands for health care services. for example, recent
evidence indicates that the number of hospital days for elderly
patients is greater than for all children aged 15 and younger.

2older adults use a disproportionate amount of health-care services,

including drugs.

3polypharmacy, the prescribing of many drugs at one time, is

common in older adults. as the number and complexity of illnesses
increase with age, the complexity of drug treatment increases.

4patients may receive medications from several different physicians,

and there is no guarantee that each prescriber is aware of what the
other is doing.

5add to that the likelihood that the older patient is self-prescribing

other medications for a variety of real or perceived illnesses (or
actually and unknowingly to counteract some illness or discomfort
caused by their prescription drugs).

6unless they are asked specifically about drug use, this important
assessment information may be unknown to the physician.

7overall, drug-drug interactions have a major role in the adverse drug

responses of older adults, and the general dissatisfaction with drug
therapy (and with the health care system in general) expressed by
many elders.

8older adults take about three times the amount of drugs taken by
people under age 65. on the average, elders living in the community
receive from three to five drugs per day.

9naturally, high on the list of the most commonly prescribed drugs are
those used to treat:
1.cardiovascular disorders (e.g., heart failure, hypertension)
2.cns disorders (e.g., depression, dementia, psychosis)
 3.pain and inflammation (anti-arthritic drugs).

• self-prescribed drugs include:

1. those affecting the gi tract (antacids,
antidiarrheals, laxatives, and cathartics are
“popular” or, at least, perceived as important an
innocuous by the users).
2. the cns (sleep aids) drugs,
3. analgesic and anti-inflammatory drugs.

1then you need to consider the potential impact of various nutritional

supplements and nontraditional medications (including some of
dubious value which are advertised as nutritional supplements, rather
than as drugs). in most cases the biologic effects of these products
are largely unknown.
we know even less about how they might interact with traditional
drugs.

1in too many cases, when you are dealing with multiple disorders and
a dozen or more drugs (or even a fewer number), it becomes virtually
impossible to keep control of everything, avoid significant drug
interactions, and prevent drug-induced side effects from becoming
almost as problematic as the disorders for which they are being
given.

2in too many cases, even when the only drugs taken are prescribed
drugs and the number is relatively small, therapy falls far short of the
goal of causing no harm.

pharmacokinetic changes in older adults

1as we grow older, drug absorption, distribution, metabolism and

excretion can be altered through the combined influences of age-
related physiologic changes, disease, nutrition, and drug therapy.

1the major pharmacokinetic changes are explained in the following

discussion and summarized in table 5, on the next page. all of them
help explain why, in most cases, drug doses should be reduced in
elderly persons, and why especially careful monitoring of therapy
(and communication and coordination between multiple
2prescribers) is so important.

3a common but incorrect assumption that relates to older individuals

overall, and perhaps to drug therapy in particular, is that “everything
deteriorates” with age. although many of the factors that affect
pharmacokinetics do decline as one reaches the age of 65 and
beyond (and some actually start to decline after the age of 50, and for
some people even before then), many do not decline intrinsically. that
is, many of the physiologic changes that occur as we age, and that
we ascribe to aging per se, really don’t change at all.
4instead, the changes of such factors as cardiac output, or hepatic or
renal function, occur secondary to diseases that are more common in
elderly individuals. they do not reflect senescence in the truest sense.
5when thinking about how pharmacokinetic changes in the elderly
might necessitate changes in drug therapy, you need to think beyond
the obvious. it may be obvious, for example, that a patient will (and
sometimes must) receive a drug that depends greatly on hepatic
metabolism (or renal excretion) as a prime way to terminate its effects
in the body, even if or when that patient has liver disease (or renal
disease).
6what is not so obvious, but is so critically important to remember, is
that most drugs depend on the interrelated function of several organs
for their entry into, and elimination from, the body. it’s naïve to believe
that for the patient with a “bad liver,” all one needs to do is choose an
alternative but otherwise similar drug that isn’t metabolized (or is
metabolized much less) and administer it carelessly.
7moreover — and this appears to be especially true for the elderly —
although a particular disease may appear to alter the function of
mainly one organ (e.g., the liver), other organs and organ systems,
and their essential functions, can be affected too. a good example of
this is heart failure, which is much more common in the elderly.
8the heart does not absorb, metabolize, or excrete drugs. however,
because one of its prime functions is to deliver blood to the key
absorptive, metabolizing, and excreting organs, heart dysfunction can
cause a host of pharmacokinetic changes that complicate therapy.
likewise, drugs that exert a major effect on a particular organ or organ
system can also have an impact on pharmacokinetic processes
 carried out by other organs.

9other common age-associated conditions that can have a

widespread impact on pharmacokinetics include dehydration,
malnutrition, hyper-or hypotension, diabetes, and pulmonary disease.

table 5. summary: some physiologic characteristics of older adults,

and their pharmacokinetic consequences

consequence characteristic

narrower distribution, increased blood levels, of water decreased body water

soluble drugs content

decreased blood levels of highly lipid-soluble drugs increased body fat

increased free levels (and effect, metabolism/excretion) decreased serum albumin

of drugs that are normally highly protein-bound levels

more complete and/or faster absorption of drugs that

are completely or partially inactivated by gastric acid, or relatively lower gastric
drugs that are mainly ionized at low ph acid-secreting capacity

cardiac output falls about 30% between the ages of 50

and 65 years; splanchnic and hepatic blood flow decline decreased cardiac output
by about the same amount; renal blood flow (and gfr) and local blood flow
fall to about half their values measured at age 50.
locally reduced blood flow can reduce enteric
absorption of drugs, and/or reduce drug metabolism
and excretion. excretory changes are the most
important.

decreased metabolism (and longer half-life) of drugs

depending on hepatic metabolism; excessive initial
effects of some drugs that normally depend on first- decreased liver mass and
pass metabolism; liver mass declines about 30% hepatocyte function
between age 50 and 65.

---------------------
1finally, don’t underestimate the capacity of one determinant of
pharmacokinetics in the older individual to compensate for changes in
another. for example, circulating levels of many hormones stay
remarkably constant in the later years of life. although hormone
synthesis and release may truly be reduced, for example, changes of
other factors may be sufficient to compensate for the reduced
synthesis, thereby maintaining circulating hormone levels at levels
similar to those found in younger adults.

absorption
1of the four main pharmacokinetic factors that govern the fates and
actions of drugs, absorption seems to be the least affected. (although
it might be affected least, the changes can be important nonetheless,
and we will focus on absorption of drugs administered orally).

2if there are changes, they usually involve the rate at which drugs are
absorbed from the gi tract. the bioavailability (extent of absorption) of
oral doses is affected much less and much less often.

3gastric ph, which affects the ionization and diffusibility of drugs,

tends to increase because of decreased gastric acid secretion. there
are also decreases in gut motility, surface area (at least in terms of
surface area that can functionally absorb drugs well), and blood flow.

4these changes are more likely caused by disease, nutritional status,

and drug therapy, than by simple age-related physiologic changes.
overall, neither the rate of drug absorption from the gut, nor the
amount of a dose that is absorbed (bioavailability) is changed much.

5however, as noted below, significant age-associated decreases in

hepatic metabolism (and hepatic blood flow) can make it appear as if
greater amounts of some drugs have been absorbed.

distribution
1the lean body mass of an older adult decreases by 25% to 30%.
actually, this change starts much earlier in life. estimates indicate that
women lose, on average, about 5 kg of lean body weight between the
ages of 25 and 75 years. men lose between two- and three times that
much over the same time span.

1body water content decreases, and body fat increases, with and
generally in proportion to the fall of total body weight. the fraction of
total body water comprised of extracellular water seems to shrink the
most in parallel with declines of lean body mass.
2plasma concentrations of water-soluble drugs are increased
because the drugs are distributed throughout a smaller relative
volume of body water. plasma concentrations of lipid-soluble drugs
are decreased because of distribution into a relatively greater amount
of fat.

3lean muscle mass decreases concomitant with aging and the fall of
lean body mass. this contributes to an age-related fall of the basal (or
resting) metabolic rate, which also affects drug metabolism and
excretion. part of the fall of basal metabolic rate that occurs with age
depends on the individual’s life-style: it falls much less in individuals
who remain active, through exercise, and falls much more in those
who have a sedentary life style.

4serum albumin levels usually decrease in the later years, although

the changes may not be as significant or consequential as was
previously thought. the declines, no matter how great quantitatively,
usually reflect decreases in albumin synthesis more so than albumin
loss via renal tubular changes (excretion).

5nonetheless, since many drugs tend to bind to albumin, the

decreased number of binding sites will lead to a proportionately
higher number of unbound and therefore pharmacologically active
molecules in the circulation. as a result, greater and potentially more
adverse effects may occur unless the dose is reduced properly.

6multiple drug therapies, common in the older adult, may result in

competitive displacement of some drugs from a limited number of
protein binding sites, thereby increasing free blood concentrations
even more.

metabolism
1three main factors seem to contribute to age-associated decreases
in drug metabolism, mainly in the liver:
1.decreased activity of the liver’s drug metabolizing enzymes.
2.decreased hepatic blood flow, which is responsible for delivering
drugs to their site of metabolism.
3.decreased functional liver mass.
• disease, altered nutritional status, and drug therapy seem to
affect hepatic enzyme activity and blood flow the most.
• decreased liver function, which can be monitored fairly well with
simple blood tests (e.g. by measuring ast and alt) has a particularly
great impact on orally administered drugs that ordinarily undergo
extensive hepatic first-pass metabolism.

• overall, reduced metabolism can increase the amount of some

drugs that enter the bloodstream. in the case of drugs subjected to
first-pass metabolism, the excessive rise of blood levels is especially
important when drug therapy is initiated, i.e., before the enzyme
systems become saturated after repeated dosing.

• reduced metabolism, whether first-pass or otherwise,

simultaneously decreases the rate at which drugs appear to be
cleared from the bloodstream as the result of metabolism. in view of
this, diminishing liver function is one more reason for advising that
drug doses be reduced, and monitored much more carefully, in the
older patient.

• there’s not much clinical data to make quantitative assessments

of age-related changes in drug metabolism in general, or with respect
to specific aspects of hepatic drug metabolism.
• that’s because most of the data have been collected from
animal studies. nonetheless, and clearly, “changes” in the metabolic
clearance of certain drugs that depend on certain cofactors,
enzymes, or enzyme families for their biotransformation occur.

• however, it isn’t known for sure whether (for example)...

o there is an “overall loss” of hepatic enzymes;
o otherwise functional enzymes are damaged (e.g., by free
radical-mediated attack);
o there may be increased synthesis of replacement
enzymes with functional (drug-metabolizing) capacities
lower than younger forms of the enzyme;
o there is a loss of enzyme cofactors; or
o other alterations in the hepatocytes’ intracellular milieu
occur.
excretion
reduced renal drug excretion accounts for more adverse drug
effects in the elderly than any other single pharmacokinetic
factor.
about two out of every three older adults have some clinically
significant age-related renal function decline or dysfunction. the major
changes seem to involve reduced glomerular filtration and, to a lesser
extent, tubular secretion.

renal status is usually assessed as the creatinine clearance, which

can be approximated from measurements of plasma creatinine levels.
such measurements are a common part of blood tests given to most
patients, and they should be checked routinely in the elderly.

package inserts for many drugs give guidelines (note the word
guidelines) about how to modify the dose or dose interval depending
on the creatinine level or clearance value. you need to check these
recommendations too before prescribing, and be aware that the
guidelines don’t replace the need for careful and often frequent
assessment of the actual drug responses and of the patient overall.

pharmacodynamic changes in older adults

1the sections above discussed altered drug responses in the elderly

because of pharmacokinetic changes. for example, and unusually
heightened or prolonged response to a particular drug might be
explained in terms of increased or prolonged blood levels due to
decreased metabolism or excretion.

1however, there is also evidence that, compared with younger

persons, the elderly experience greater (or lesser) response to a
particular dose of some drugs even when the plasma concentration of
free (active) drug is the same, and in the “therapeutic range.” that is,
the changed response intensity is not caused by too much (or too
little) drug at active sites, but by increased or decreased responses of
the target cells to the drug molecules that are there. this is a
pharmacodynamic alteration of drug response.
1much less is known about pharmacodynamic changes than about
pharmacokinetic alterations, in part because the pharmacodynamic
changes are harder to measure.

2nonetheless, some of what is known can be helpful when adjusting

drug dosages for elderly patients, when anticipating altered and
sometimes unwanted effects, and when trying to understand why
these changes make the patient more or less “sensitive” to the effects
of a drug. what follows is a brief overview of how some of these
changes are thought to come about, with examples of each.

receptor or other cellular changes

decreased responses to some drugs may be caused by an age-
related decrease in the number of receptors with which the drug must
interact. this has been used to explain, for example, a relatively
weaker ability of drugs like epinephrine to stimulate the heart, and a
relatively weaker ability of the adrenergic blockers that can block
those receptors.

in addition, age can bring about changes in the cells’ second

messenger systems that are needed to translate the interaction
between an agonist and its receptors into the eventual pharmacologic
response.

changes in reflexes and other homeostatic mechanisms

1drugs acting on one organ or system sometimes trigger reflexes
aimed at maintaining, more or less, the status quo. however, in the
elderly some of these compensatory processes can be impaired.

1this sort of control is particularly important, and common, in the

cardiovascular system. for example, some antihypertensive drugs
can cause an abrupt fall in blood pressure — a phenomenon called
orthostatic hypotension — when the patient stands up suddenly.
normally the autonomic nervous system responds almost
instantaneously to constrict blood vessels in the legs. without this
reflex, blood would tend to pool in the legs and the brain could be
deprived of sufficient blood flow, even if for a moment, such that
dizziness, fainting, a fall, and serious injury could occur. in the elderly,
however, the protective reflexes seem to be diminished, and so the
risks are increased.

nutritional changes
1nutritional deficiencies can account for some altered drug responses
in the elderly. for example warfarin exerts its effects in the liver by
inhibiting the synthesis of vitamin k-dependent clotting factors. an
inadequate intake of vitamin k-containing foods, therefore, can
intensify the drug’s main effect, leading to abnormal or excessive
bleeding.

1it’s important to realize that a patient need not be in a state of

general, symptomatic malnutrition or malnourishment for some
adverse drug effects to occur. a deficiency of just one nutrient can
have significant effects on the responses to specific drugs. it is also
important to assess for factors, age-related and otherwise, that could
affect nutritional status.

2things to look for include:

1.chronic diarrhea or vomiting.
2.diminished appetite or taste
3.difficulties with chewing or swallowing.

• some problems can be caused by age, disease, psychologic

factors (e.g., depression), and even by therapy with certain other
drugs. it is even important to consider economic factors that could
affect a patient’s ability to buy and eat a proper, healthy diet.

side effects in the elderly

1the consequences of diseases encountered by the elderly, or the
administration of drugs used to treat them, are too numerous to
discuss separately. however, we can make some generalizations
about some common drug-induced side effects that are most likely to
occur and be bothersome, since some of them can be caused by
several of the drug groups often given to (or self-prescribed by) the
elderly.

1it is important to note that without proper recognition and

management, drug side effects can become so intense and
bothersome (let alone dangerous) that they outweigh some of the
desired therapeutic benefits. this may cause the patient to not take
their drugs are recommended, or to stop therapy with one or more
drugs altogether.

antimuscarinic effects
1many drugs and groups of drugs cause antimuscarinic
(anticholinergic, or atropinelike) effects. these are effects that occur
because drugs block the muscarinic subtype of receptors for
acetylcholine and parasympathomimetic drugs.

1drugs having antimuscarinic properties that are commonly used by

the elderly include mydriatics (pupil-dilating drugs), drugs used to
manage symptoms of colds and hay fever (antihistamines), and drugs
used for certain types of mental illnesses (e.g., antidepressants and
antipsychotics).

2antimuscarinic effects can worsen glaucoma; prostate, bowel and

bladder problems; and hypotension.

hypotension
1as noted above, several age-associated pharmacokinetic and
pharmacodynamic changes occur in the cardiovascular system. these
can contribute to a prolonged and or excessive lowering of blood
pressure, or acute but significant (and dangerous) posture related
hypotension.

1this problem is caused not only by drugs given specifically to lower

blood pressure (antihypertensive drugs), but also by other drugs that
may lower blood pressure as a usual side effect.

2examples of drugs used to treat insomnia and other sleep disorders,

anxiety, depression, psychosis, parkinsonism, seizure disorders, pain,
and even some manifestations of common allergies or the cold and
flu. and most, if not all, of these drugs can cause other relatively
common and problematic side effects for the elderly, as noted next.

sedation, confusion, ataxia

1the most common side effects caused by drugs with cns depressant
activity are sedation and drowsiness, confusion and disorientation,
and ataxia. some drugs, notably some of the benzodiazepines (e.g.,
diazepam — valium) that are considered “preferred” drugs for anxiety
and insomnia, can also produce short-term memory loss (amnesia) or
“hangover,” depending on their individual pharmacologic profiles.

1besides the obvious drawbacks of being drowsy, confused, or

uncoordinated, there are some real and serious dangers such as
those posed by driving a car, operating dangerous machinery, or
even walking, in an “impaired” state.

2the problems caused by many drugs can be aggravated by

consuming even small amounts of alcohol, by hypotension or
dehydration, and by other factors that are more likely to occur in the
elderly.

3another risk imposed by cns depressants is their ability to mask or

mimic cns changes that otherwise could be valuable in recognizing or
diagnosing underlying disorders such as stroke, parkinsonism,
alzheimer’s, dementia, and depression.

compliance and noncompliance

medication compliance and compliance (or, as known by their more
politically correct alternatives, adherence and nonadherence) are
important (although not unique) considerations in drug therapy of
older adults.

it appears that, on average, elderly persons are no less compliant

with medications than younger persons. however, for elders some
causes of noncompliance may be more important or more common
than they are for others, and these should be assessed for when
trying to optimize drug therapy.

the majority of cases of noncompliance in the elderly are intentional.

1. polypharmacy, a leading cause of adverse drug effects in the
elderly, also makes the medication plan inherently difficult to follow.
this includes use of both drugs, which may be ordered by several
physicians (with the possibility for medication duplication or
unrecognized interactions), and with self-prescribed drugs. since it’s
safe to assume that multiple illnesses will be linked to the prescribing
of more drugs (one or more for each illness), then one can also state
that multiple or advanced illnesses contribute to noncompliance

one obvious difficulty for the patient is knowing which medications to

take; and when, not only with regard to the time of day but also with
respect to meals or other medications that might interfere with (for
example) drug absorption. the more complex the treatment plan, the
greater the chance for noncompliance, whether the compliance is
intentional, unintentional, or simply unavoidable because the regimen
is so complicated.

one way to minimize the problems of polypharmacy is to keep the

medication regimen as simple as possible: the fewest number of
drugs, and the smallest number of daily doses and administration
times.

2. financial considerations may make it difficult for the elderly person

to decide whether purchasing medications (even paying for a modest
co-pay) takes priority over other necessities of life (buying food,
paying the rent). it can also influence a decision to self-medicate with
cheaper (although not necessarily less effective) drugs instead of
those that are prescribed by the physician.

use of self-medicating drugs can cause additional problems in its own

right. if you, the prescriber, are aware of (or can actually recommend
and supervise their use), then you might be able to modify other
aspects of drug therapy to minimize the number or severity of side
effects (e.g., from drug interactions).

of course, if you are unaware of drug use by your patient you will be
clueless in many ways. one of the greatest dangers of this ignorance
is a more difficult task of determining why the medication regimen
you’ve prescribed isn’t working or is causing so many problems (e.g.,
adverse effects). you can spend and waste much time and money
juggling drugs and ordering tests if you aren’t fully aware of your
patient’s drug taking.

the only way to find out, of course, is to ask and ask about explicitly
“what drug(s) are you taking.”
3. whether because of financial reasons, a period of symptom relief,
or an episode of unpleasant side effects, medications may go unused
and be saved until the patient feels a need to take them again. some
medications may become outdated during this time, losing some or
all of their activity by the time they are taken again.

many patients simply feel they do not need some (or even any) of the
drugs prescribed for them, or at least they don’t need such high
doses.

4. physiologic changes from aging and illness can cause such

problems as forgetfulness, confusion, or anorexia, which can lead to
unintentional noncompliance despite the best intent to take
medications as directed.

5. special senses, physical strength, and dexterity may be impaired.

auditory problems may make it difficult to hear advice about therapy,
even though the best of verbal instructions might have been given.

visual impairments can make it difficult to read written directions or

labels of medication containers, or to identify the shape, size, or color
of a medication.

altered taste (and smell) may make it difficult to distinguish one liquid
medication from another that is packaged in a similar container and
looks alike in other ways.

conditions such as arthritis can make it difficult to open medication

containers, most of which have child-resistant caps.

6. habits, practices, and social or cultural beliefs held for many years,
which previously kept the patient quite well, may limit willingness to
comply with therapy. some of these factors may include the use of
nonprescription drugs or other remedies (“traditional” or not), or
certain diets, that can have an influence on drug taking or drug
responses. such knowledge of “myself, the way i was for years,:” can
make taking medications, or tolerating the side effects or essential
monitoring they impose, no more acceptable than the illness for
which those drugs are being taken.

7. personal loss or grief, especially of recent onset, can be a

disincentive to taking medications.
-------------------------
many approaches that foster compliance and assess for it in any
patient should be applied to the elderly. in addition, the unique causes
of noncompliance in elders should receive special attention.

an inability to hear instructions clearly should never be an “excuse”

for noncompliance, since clearly written instructions should be
provided. if possible (and it’s often necessary), those instructions
should be provided to another adult (friend or family member, for
example) who might share in or take major responsibility for
managing the therapy. instructions written in large type can help
some patients.

given the prevalence of polypharmacy for elders, it is also important

to obtain a thorough medication history, inquiring about duplicate or
interacting drugs that might be prescribed by other physicians; and
about nonprescription drug use, including which medications are
taken, how often, and why the patient perceived the need to take
them.

in some cases you can identify alternative combination drug products

that would allow simultaneous administration of two medications at
once; or other alternatives with longer durations of action, which
would reduce the frequency with which the drug must be taken. (of
course, the disadvantage of longer-acting alternatives is that side
effects or adverse responses, whether due to excessive doses or
drug-drug interactions, will last longer.)

careful assessment and planning can also gain insight into the
appropriateness of dosages. reviewing lab test results for drug levels
or indicators of impaired organ function is useful, if not essential.
however, lab test results should never take the place of assessing for
subjective and objective evidence of desired drug effects (e.g.,
symptom relief), unwanted side effects and interactions, and insight
into the patient’s subjective responses to medication and disease.

don’t lose sight of the possibility that if noncompliance goes

undetected as the cause of an inadequate drug response; you may
assume that the drug truly is not working. as a result, you may
needlessly start raising the dose, switching to another drug, or adding
more drugs to boost the effects of the first one.
we’ll assume (hope) that you’ll give your patients adequate
instructions to enhance compliance, and you’ll assess for it. what if
you determine they are not compliant? you’ll need to figure out why,
and then you’ll need to work with the patient to find acceptable
solutions to the noncompliance problem — you shouldn’t just
“automatically” change your drug therapy plan.
case study #1
cs is a 58 year old female who presents to your office with a 4 day history of
s/sx consistent with a bacterial uri. she is otherwise healthy. her current
medications include hrt and ca + vit d. she receives a prescription for
levofloxacin 500 mg po qd. 5 days later, she calls your office because her
symptoms have not subsided.

•what questions would you ask cs?

•what are possible reasons for treatment failure?
•would you change cs’s therapy? if so, how?

case study #2
gb is a 67 year old male with a significant asthma history. he presents to the
ed with n/v, tremors, and a “racing heart.” he had been stable on
theophylline 300 mg po tid, fluticasone 220 mcg bid, and albuterol prn. he
has had no changes in medication or diet recently. he stopped smoking 8
days ago. pertinent labs indicate a theophylline level of 52 mcg/ml and
k=2.8. he is experiencing sinus tachycardia.

•what is gb’s diagnosis?

•how did he get to this state?

•how would you manage gb?

•would you alter is medication regimen?
•would you order any additional tests? if so, what/when?
•what type of follow-up would be necessary?

case study #3
kl is a 41 year old female who presents to the office feeling “disoriented.”
she states that her urinary patterns have changed (decreased.) she has also
gained a couple of pounds since her last visit. she has hypertension that is
well controlled with enalapril 20 mg qd and osteoarthritis that is controlled
with naproxen 1200 mg qd. her physical exam is otherwise unremarkable.
labs come back later that afternoon indicating bun 44, scr 3.8, & a slightly
elevated k.

•could any of her medications contributed to her acute renal insufficiency?

which one?
•would celecoxib be less likely to contribute to renal insufficiency compared
to naproxen?
•how would you manage this patient?
•how would you treat her ari?
•how would you change her medication regimen?

case study #4
rl is a 78 year old female with significant cv dysfunction. she is admitted to
the hospital in acute v fib. medication include digoxin, asa, metoprolol,
calcium, and docusate. she is begun on amiodarone. her heart rate &
rhythm trend toward normal. she later develops mental status changes, n&v,
and hyperkalemia. a dig level comes back 3.8 ng/ml.

•what drug interaction may have contributed to ms rl’s current status?

•how would you manage ms. rl?
•in retrospect, would you have done anything differently with this patient?
case study #5
xl is an obese 43 year old male with hypercholesterolemic, htn, and
atherosclerosis. his cholesterol being treated with atorvastatin 20 mg qd and
his ldl is lowering nicely. his hld is also increasing. however his
triglycerides are still significantly elevated after 12 weeks of therapy.
gemfibrizil 600 mg bid is then added to his current regimen. he returns for
follow up three months later and mentions that he has been having some
muscle cramping/pain in his legs and asks for something for the pain.

•how would you proceed with xl’s treatment?

•would you order any labs?
•could a drug interaction have occurred? what?
•would a different hmg agent have been safer?

case study #6
1jd is a 37 year old male who is being treated with warfarin for dvt. he is
stable on 5 mg of warfarin daily (inr = 2.4) and is otherwise healthy. he
develops a lower respiratory tract infection and is prescribed ofloxacin 400
mg po bid for 10 days. one week later he calls the office with a profuse
nosebleed that he is unable to control. he returns to the office and his inr is
found to be 5.8. his dose of warfarin is held for the two doses then restarted
at 2.5 mg qod, alternating with 5 mg.

•what are potential causes of jd’s change of coagulation status?

•can you recommend a safer alternative to ofloxacin?
•what would you expect jd’s inr to be next week?

complementary and alternative medicine (cam)

what is cam?

as defined by the american national center for complementary and

alternative medicine (nccam), it is a group of diverse medical and
health care systems, practices, and products that are not presently
considered to be part of conventional medicine. while some scientific
evidence exists regarding some cam therapies, for most there are key
questions that are yet to be answered through well-designed scientific
studies — questions such as whether they are safe and whether they
work for the diseases or medical conditions for which they are used.

the list of what is considered to be cam changes continually, as those

therapies that are proven to be safe and effective become adopted into
conventional health care and as new approaches to health care emerge.

are complementary medicine and alternative medicine different from

each other?

yes, they are different.

complementary medicine is used together with conventional medicine. an

example of a complementary therapy is using aromatherapy to help
lessen a patient's discomfort following surgery.

alternative medicine is used in place of conventional medicine. an

example of an alternative therapy is using a special diet to treat cancer
instead of undergoing surgery, radiation, or chemotherapy that has
been recommended by a conventional doctor.
what is integrative medicine?

integrative medicine, as defined by nccam, combines mainstream medical

therapies and cam therapies for which there is some high-quality
scientific evidence of safety and effectiveness.

what are the major types of complementary and alternative

medicine?

nccam classifies cam therapies into five categories, or domains:

• alternative medical systems

alternative medical systems are built upon complete systems of theory

and practice. often, these systems have evolved apart from and earlier
than the conventional medical approach used in the united states.
examples of alternative medical systems that have developed in
western cultures include homeopathic medicine and naturopathic
medicine. examples of systems that have developed in non-western
cultures include traditional chinese medicine and ayurveda.

• mind-body interventions

mind-body medicine uses a variety of techniques designed to enhance the

mind's capacity to affect bodily function and symptoms. some
techniques that were considered cam in the past have become
mainstream (for example, patient support groups and cognitive-
behavioral therapy). other mind-body techniques are still considered
cam, including meditation, prayer, mental healing, and therapies that
 use creative outlets such as art, music, or dance.

• biologically based therapies

biologically based therapies in cam use substances found in nature, such

as herbs, foods, and vitamins. some examples include dietary
supplements, herbal products, and the use of other so-called "natural"
but as yet scientifically unproven therapies (for example, using shark
cartilage to treat cancer).

• manipulative and body-based methods

manipulative and body-based methods in cam are based on manipulation

and/or movement of one or more parts of the body. some examples
include chiropractic or osteopathic manipulation, and massage.

• energy therapies

energy therapies involve the use of energy fields. they are of two types:

o biofield therapies are intended to affect energy fields that purportedly

surround and penetrate the human body. the existence of such fields
has not yet been scientifically proven. some forms of energy therapy
manipulate biofields by applying pressure and/or manipulating the
body by placing the hands in, or through, these fields. examples
include qi gong, reiki, and therapeutic touch.

o bioelectromagnetic-based therapies involve the unconventional use

of electromagnetic fields, such as pulsed fields, magnetic fields, or
 alternating current or direct current fields.

dictionary of terms

aromatherapy: aromatherapy involves the use of essential oils (extracts

or essences) from flowers, herbs, and trees to promote health and
well-being.

ayurveda is a cam alternative medical system that has been practiced

primarily in the indian subcontinent for 5,000 years. ayurveda
includes diet and herbal remedies and emphasizes the use of body,
mind, and spirit in disease prevention and treatment.

chiropractic ("ki-roh-prac-tic") is a cam alternative medical system. it

focuses on the relationship between bodily structure (primarily that of
the spine) and function, and how that relationship affects the
preservation and restoration of health. chiropractors use manipulative
therapy as an integral treatment tool.

dietary supplements: a dietary supplement is a product (other than

tobacco) taken by mouth that contains a "dietary ingredient" intended
to supplement the diet. dietary ingredients may include vitamins,
minerals, herbs or other botanicals, amino acids, and substances such
as enzymes, organ tissues, and metabolites. dietary supplements come
 in many forms, including extracts, concentrates, tablets, capsules,
gelcaps, liquids, and powders. they have special requirements for
labeling. dietary supplements are considered foods, not drugs.

electromagnetic fields: electromagnetic fields (emfs, also called electric

and magnetic fields) are invisible lines of force that surround all
electrical devices. the earth also produces emfs; electric fields are
produced when there is thunderstorm activity, and magnetic fields are
believed to be produced by electric currents flowing at the earth's
core.

homeopathic medicine is a cam alternative medical system. in

homeopathic medicine, there is a belief that "like cures like" meaning
that small, highly diluted quantities of medicinal substances are given
to cure symptoms, when the same substances given at higher or more
concentrated doses would actually cause those symptoms.

massage therapists manipulate muscle and connective tissue to enhance

function of those tissues and promote relaxation and well-being.

naturopathic medicine is a cam alternative medical system in which

practitioners work with natural healing forces within the body, with a
goal of helping the body heal from disease and attain better health.
practices may include dietary modifications, massage, exercise,
acupuncture, minor surgery, and various other interventions.
osteopathic medicine is a form of conventional medicine that, in part,
emphasizes diseases arising in the musculoskeletal system. there is an
underlying belief that all of the body's systems work together, and
disturbances in one system may affect function elsewhere in the body.
some osteopathic physicians practice osteopathic manipulation, a full-
body system of hands-on techniques to alleviate pain, restore function,
and promote health and well-being.

qi gong ("chee-gung") is a component of traditional chinese medicine

that combines movement, meditation, and regulation of breathing to
enhance the flow of qi (an ancient term given to what is believed to be
vital energy) in the body, improve blood circulation, and enhance
immune function.

reiki ("ray-kee") is a japanese word representing universal life energy.

reiki is based on the belief that when spiritual energy is channeled
through a reiki practitioner, the patient's spirit is healed, which in turn
heals the physical body.

therapeutic touch is derived from an ancient technique called laying-on

of hands. it is based on the premise that it is the healing force of the
therapist that affects the patient's recovery; healing is promoted when
the body's energies are in balance; and, by passing their hands over the
patient, healers can identify energy imbalances.
 herbology
historical context of herb usage

1physical evidence dates back 60,000 years

2 all cultures have traditions of herb use for healing

3 2000 bc - first known materia medica in samaria

4 1st century - chinese materia medica

5 25% of prescription drugs derived from plants

6 80% of world population uses herbal medicine for primary care

7herbal remedies fall into the category of complementary medicine.

8misconceptions regarding their safety and efficacy are common.

9the fact that a substance is natural does not guarantee safety.

10patients should know about compatibility and possible interactions

when taking herbs and drugs simultaneously.

11crude herbs are not regulated for purity and potency therefore drug –
herb interactions can be caused by impurities e.g. allergens, pollens,
spores; or there might be a batch to batch variability.

summary on some important medicinal herbs

ehinacea ( purpurae; pallida; augustifolia)
Achemical constituents: root extract of e. pallida contains.

1- flavonoids.
 2- lipophilic constituents.

- alkamides.

- polyacetylenes.

3- hydrophilic constituents.

- echinoside.

- chicoric acid.

- caffeic acid.

- h2o sol polysaccharide.

n. b. alkamides, chicoric acid & h2o soluble polysaccharides give the herb
the immune modulating properties.

b- pharmacology :

1. immune modulation (↑ phagocytosis).

2. anti – inflammatory (↓ cox & 5- lox).

c-uses:

1.enhance immunity in upper respiratory tract infection (cold and

flu).

2.might enhance hematologic recovery following chemotherapy

(investigationally).

3.adjunct in treatment (tx) of u.t. infection.

d-adverse effects:

1.flu like symptoms.

2.gi upset – hepatotoxicity specially if given with hepatotoxic

drugs.

3.headache – dizziness.

4.occasionally allergic reactions.

e- drug – drug interactions (ddi):

1- + immunosuppressants → ↑ immunesystem → counteracts drugs’

effects.

n.b. if taken > 8 weeks (not recommended) → immunosuppressent

enhance drugs’ effects.

2- + hepatotoxic drugs e.g. methotrexate or ketoconazole → ↑

hepatotoxicity.

f- dosing 900 mg / d (pallida root extract).

feverfew (tanacetum parthenium)

Achemical constituents:

1- flavonoids.

2- monoterpenes (e.g. camphor).

 3-sisquiterpenes: parthenolide.

a- 1ary active ingredient.

b- found in seeds & leaves.

c- mechanism of action: bind covalently to thiol group of proteins.

d- feverfew products should contain not less than 0.2 %

parthenolide.

e- prolonged storage → polymerization of

parthenolide.

Bpharmacology:

1- migraine.

aused for prophylaxis: parthenolide ↓ 5–ht release

from platelets. in vitro → ↓ platelet
aggregation.

2- anti – inflammatory → ↓ pgs, thromboxane, ltb4, cytokines (tnfα & i l

– 1) → can be used in rheumatoid arthritis.

3- other actions:

a- ↓ histamine release.

b- antimicrobial against g + bacteria.

c- uses:

1prophylaxis against migraine.

 2menstrual problems.

d- adverse effects:

1mouth ulcers.

2gi upset.

e- ddi:

1- + anticoagulants or + antiplatelets → additive ↑ bleeding risk.

2- + nsaids → ↓ herb effects in migraine tx.

3- + fe → tannin content in herb ↓ fe absorption.

f- dosing :

2-3 fresh leaves or 125 mg/d dried leaf formulations.

garlic (allium sativum)

a- chemical constituents

1active ingredients are organosulfur compounds e.g. allicin

(responsible for odor of garlic)

alliin allicin
↑ temp + ↓ ph → allinase degradation

∴ give as enteric coated to prevent enzyme degradation.

b- pharmacological effects & uses

1. cv effects:

a.allicin → ↓ hmg co-reductase.

b.antiplatelet effect

c.antioxidant action

d.beneficial in atherosclerosis.

2. endocrine effects:

hypoglycemic effect.

3. antimicrobal actions:

allicin → active against bacteria (g+, g-); fungi (candida albicans);

protozoa (entamoeba histolytica).

mechanism: ↓ thiol-containing enzymes needed by the organism.

4. antineoplastic effects:

a.↓ procarcinogens for colon, esophageal, lung, breast, stomach cancer.

mechanism: detoxification of carcinogens & ↓ carcinogen activation

c- adverse effects:

1. nausea 2. hypotension

3. allergy 4. bleeding (rare).

d- ddi:

1.+ anticoagulants, antiplatelets → additive effect.

2.+ hypoglycemic drugs → hypoglycemia

e- dosage:

1products should contain 1.3 % alliin.

2enteric-coated formulations are recommended.

3600-900 mg/d powdered garlic (equivalent to ½ -1 bulb of raw garlic.

ginko (ginko biloba):

a- chemical constituents:

1should contain 24% flavonoids, 6% terpens.

2extract is prepared from leaves

3active ingredients:

1.flavonoids.

2.terpenoids
b- pharmacological effects & uses:

1. cv effects:

a. ↑ blood flow, ↓ blood viscosity (antiplatelet activity), enhancement of

endogenous no.

1used in intermittent claudication (120 mg/d).

2. metabolic effects:

a. antioxidant and radical scavenging properties (flavonoid action).

1↓ markers of oxidative stress in patients undergoing coronary artery by-

pass surgery.

3. cns effects:

a. ginko for 3-4 weeks in animals →

(i) ↑ m, α2, 5-ht1a, ↓ β receptors densities.

(ii) ↑ serum levels of ach, ne & ↑ synaptic reuptake of 5-ht.

(iii) ↓ mao – a & b, ↑ gaba levels.

1used in tx of:

(i) cerebral insufficiency.

(ii) dementia of alzheimer type.

4. miscellaneus effects:

a. ginkgolide b → paf antagonism → antiplatelet & anti-inflammatory

effects.

b. studied in:

i)allergic & asthmatic bronchoconstriction.

ii)erectile dysfunction.

iii)tinnitus, hearing loss.

iv)memory loss in young patients

v)muscular degeneration

1insufficient evidence to warrant clinical use.

c- adverse effects:

1. bleeding

2. nausea, headache, diarrhea, anxiety.

d- ddi:

1.+antiplatelets, anticoagulants → additive bleeding risk

2.+anticonvulsants → ↓ drug effect → seizures

3.+tricyclic antidepressants (tca) or drugs which ↓ seizure threshold →

risk of seizures
 4.+maoi → ↑ risk of manic episodes, headache, tremors.

5.+garlic → bleeding risk

e- dosing:

1dried extract (containing 24% flavone glycosides, 6% terpene lactones).

2120-240 mg/d of dried extract.

3in 2-3 doses.

4onset after 2-4 weeks.

ginseng (panax ginseng, panax quinquefolium)

a- chemical constituents:

1. active ingredients: ginsenosides (panaxoside)

a. triterpenoid saponin glycoside.

b. highest concentration in the plant root.

c. formulations should contain 7% ginsenosides.

2. flavonoids, polysaccharides, others.

b- pharmacological effects and uses:

1.ergogenic (energizing) activity.

2.nootropic (mind- enhancing activity).

3.anti-stress.

• used to:

a. improve physical + mental performance.

 b. provide resistance to stress.

c. enhance immune function.

4. anti-inflammatory; antiplatelets.

5. analgesia.

6.improved glucose homeostasis, but → hypoglycemia

c- adverse effects:

1.estrogenic effects → mastalgia, vaginal bleeding.

2.cns stimulations → insomnia nervousness.

3.hypertension if high doses (> 3g/d) are used.

d- ddi:

n.b. be cautious in patients taking, psychiatric, estrogenic or hypoglycemic

medications.

1.+ maoi (e.g. phenelzine), or neuroleptics → manic behavior.

2.+estrogen or corticosteroids → ↑ adverse effects of the drugs.

3.+hypoglycemics → hypoglycemia.

4.+anticoagulants, antiplatelets → bleeding.

5.+digoxin → ↑ drug concentration.

6.+drugs which cause gynecomastia e.g. digoxin, spironolactone,

methyldopa phenothiazines → additive effect (herb contains
 estrone, estroil, estradoil).

7.+opioids → ↓ opioid effectiveness.

e- dosing:

1.1-2 g/d crude panax ginseng root (1g is equivalent to 200 mg extract).

f- siberian ginseng (eleutherococcus senticosus):

1.not a panax.

2.active ingredient is eleutherosides.

3.used to improve endurance.

4.+digoxin → ↑ drug levels.

5.↑ blood pressure → contra-indicated in hypertension.

6.dose 2-3 g/d of crude root.

kava (piper methpsticum)

a- chemical constituents:

1kava root contains the active ingredients:

1. kavalactones (kavapyrones) e.g. kawain (kavain), methysticin, yangonin.

b- pharmacological effects:
1. cns effects:

a. drowsiness, sedation

mechanism: unknown, could be:

(i) ↑gaba- a receptors.

(ii) ↑ number of gaba binding sites.

(iii) ↓ glutamate release.

(iv) ↓ ne uptake or da antagonism.

b. mild anticonvulsant in animal

mechanism: could be prolonged inactivation of voltage dependent sodium

channels.

c. analgesia.

mechanism: could be ↑ opioid receptors.

2. antiplatelet effect:

kavain → ↓ cox.

c- uses:

1. anxiety + sleep disorders

1slow onset (4-8 weeks).

 2not in patients with acute symptoms of anxiety or panic attacks.

d- adverse effects: (mild at recommended dose)

1.tingling in mouth and gi upset.

2.sedation, euphoria, visual & auditory changes.

3.psychologic dependence, no reports on physiologic dependence.

4.may alter uterine tone → not in pregnancy, kavalactones are excreted

in milk → not in lactation.

5.dystonic extra pyramidal reaction (torticollis, oculogyric crisis, painful

twisting trunk movements) → not in parkinsonism.

6.skin rash, facial swelling, photosensitivity (reversible on drug

cessation) with chronic consumption.

e- ddi:

1.+cns depressants (alcohol, antipsychotics, benzodiazepines) →

additive sedative effects.

2.+cimetidine → disorientation.

f- dosing:

1. anxiolytic:

50-70 mg tds of purified kavalactones (equivalent to 100 – 250 mg tds of

dried kava root).
2. hypnotic:

180 – 210 mg kavalactones 30 min. before bedtime.

n.b. use should be limited to no more than 3 months to minimize

dependence.

milk thistle (silybum marianum)

a- chemical constituents:

1fruit and seeds contain lipophilic flavonolignans (silymarin)

2silimarin comprises 3 isomers:

1.silybin:

a. most potent

b. most prevalent.

c. 50% of silymarin complex.

2.silychristin.

3.silydianin.

b- pharmacological effects:

1. liver disease:

a. ↓ hepatic injury by amanita mushrooms, galactos amine, carbon

tetrachloride, paracetamol, ethanol.

mechanism:
 1↓ lipid peroxidation.

2free radical scavenger.

3↑ glutathione levels.

4↓ cyp 2e1 (involved in free radical generation).

b. anti-inflammatory:

mechanism:

1silybin ↓ lipoxygenase enzyme → ↓ lt formation

n.b. pg formation is inhibited in doses exceeding in vivo dosing capabilities

∴ silybin reduces inflammation without affecting the cytoprotective effects
of pgs

2silybin → ↓ leukocyte migration ∴ can control acute inflammation.

c. ↑ protein synthesis and hepatic cellular regeneration in diseased but not

malignant cells.

mechanism: ↑ rna polymerase i activity in non malignant hepatocytes only.

d. in hepatic cirrhosis → ↓ collagen accumulation.

mechanism: → ↓ expression of profibrinogenic cytokine tgf-β.

e. may be beneficial in management of hypercholesterolemia and gallstones

(↓ bile saturation index).
mechanism: → ↓ liver cholesterol synthesis (evidenced by ↓ biliary
cholesterol concentration).

2. chemotherapeutic effect:

a. in murine models of skin cancer, milk thistle produced → ↓ tumor

initiation + promotion.

b. in human breast & prostate cancer cell lines, it produced ↓ cell growth
and proliferation by including a g1 cell cycle arrest.

c- uses:

milk thistle may be effective in improving survival and liver functions in:

1.tx of acute and chronic viral disease.

2.tx of alcoholic liver disease.

3.tx of toxin-induced liver injury. parentral silybin is used in europe as an

antidote for amanita mushroom poisoning.

d- adverse effects:

1. loose stools with high doses.

e- ddi:

1.+hypoglycemic drugs → hypoglycemia

2.+saquinavir → ↓ effectiveness of the drug.

f dosing:

200-400 g/d (calculated as silybin) in 3 divided doses.

st. john wort (hypericum peforatum): natural antidepressant

a- chemical constituents: extract from flower contains:

1.hypercinin (maoi).

2.hyperforin. 3. others.

(1& 2 are the antidepressant constituents).

b- pharmacological effects & uses:

1. antidepressant action:

a. hypericin → ↓ mao – a & – b.

b. hyperforin → ↓ uptake of ne, 5-ht & da.

c. extract → upregulation of 5-ht receptors.

used in mild to moderate depression, side effects are < those of tricyclic
antidepressants (tca).

2) antiviral and anti carcinogenic effects:

a.parentral hypericin not the herb as a whole ( photoactivated just before

administration) :

i. ↓ viruses e.g hiv (used iv)

 ii. ↓ growth of cells in some neoplastic tissues (given intra-
lesional)

mechanism:

1. ↓ protein kinase – c.

2. ↓ singlet oxygen radical generation

c- adverse effects:

1. photosensitivity in the form of:

a.elevated, itchy, erythematous lesions

b.neuropathy associated with sun exposure (reversible), due to

demyelination of cutaneous axons caused by photo activated
hypericins

2. confusion, dizziness, fatigue

3. dry mouth, gi disturbances. 4. allergic reactions

d- ddi :

1.+ anti depressants: maoi or ssri (e.g. paroxetine) → serotonin syndrome

or hypertensive crisis

2.+ ma huang, pseudoephedrine, yohimbine → hypertensive crisis

3.+ warfarin → ↓ drug effects (herb is enzyme inducer)

4.+ digoxin or theophylline → ↓ drugs bioavailabilities

5.+ fe → tannin content of herb ↓ fe absorption

6.+ photosensitizers e.g piroxicam , omeprazole , sulfa → ↑ risk of
photosensitivity

7.+ cyclosporin + indinavir → ↓ blood levels of the drugs

8.+ benzodiazepines → ↓ effectiveness of the drugs, ↑ side effects e.g

drowsiness

e- dosing:

• 900 mg/d of dried extract in three divided doses

• onset may take 2-4 weeks

saw palmetto (serender repens)

a- chemical constituents:

1active ingredients in herb berries:

phytoserols (β-sitosterol), falvonoids, aliphatic alcohols.

2lipophilic standardized dried extracts contain 85 – 95% fatty acids and

sterols.

b- pharmacological effects & uses:

1. in vitro:

a. ↓ 5α – reductase enzyme (finasteride is the commonly used

inhibitor) this enzyme is responsible for formation of dihydro-
 testosterone (dht) from testosterone

b. ↓ binding of dht to androgen receptors

c. blockade of α1 receptors

d. ↓ prostatic growth factors

2. in patients with benign prostatic hyperplasia

a. ↓ nocturnal day time urinary frequency

b. ↑ peak urinary flow

c. finasteride is better in reducing prostate volume but causes

sexual dysfunction to a greater extent

3. the herb is used in tx of benign prostatic hyperplasia

c- adverse effects :

1. hypertension, headache, abdominal pain

2.↓ libido , impotence

d- ddi:

1. + fe → tannin content ↓ fe absorption

2. + estrogen → additive effects

e- dosing:

160 mg/bds orally of the standardized dried extract

ma huang (ephedra species)
a- chemcial constituents :

active ingredients

ephedrine

b- uses:

1. weight loss (in herbal weight loss products)

2. bronchodilator in asthma

3. enhancement of athletic and body building efforts

4. induction of euphoric state and heightening of awareness and sexual

sensations " herbal ecstasy "

c- adverse effects:

1. cns : insomnia , nervousness, tremors , headache , seizures

2. cvs: hypertension, arrhythmias ischemic heart diseases, stroke, death.

3. risk of renal stones

d- ddi:

1.+ decongestants → hypertensive crisis

2.+ methyldopa → counteracts drug action

3.+ β– blockers → counteracts drug action

 4.+ maoi → ↑ risk of hypertensive crisis

5.+ theophylline → ↑ cns stimulation & risk of seizures

6.+ st. john's wart (maoi) → ↑ risk of hypertensive crisis

e- dosing:

• 8 mg/6hrs (24 mg/d)

• should be given with the following warnings :

1. not > 7 days and don’t exceed the recommended dose or else →
adverse effects (mi, stroke, seizures, death).

2. contra indicated in patients with hypertension, hyperthyroidism, diabetes,

seizure disorders, psychiatric conditions, glaucoma, prostatic enlargement,
cardiac problems.

tumeric see table page 35

capsicum see table page 28

cascara see table page 28

chamomile see table page 28

evening primrose see table page 29

licorice see table page 32

senna see table page 33

grape seeds see table page 35

cranberry see table page 35

 yohimbine see table page 35

psyllium see table page 33

royal jelly see table page 37

selected herbs, clinical indications, herb-drug interactions

al effect drug common herb

indication
coumarin constituents and vitamin k; anticoagulants multiple, alfalfa
e use can interfere with drug therapy including (medicago
treatment of sativa)
arthritis,
asthma,
dyspepsia,
hyperlipidemi
a, and
diabetes
se electrolyte imbalance and hypokalemia; cardiac strong aloe vera latex
entiate drug toxicity glycosides, cathartic
thiazide diuretics
loss of angelica
coumarin constituents; may potentiate drug anticoagulants appetite, (angelica
peptic archangelica)
discomfort
ed by urinary acidifiers; active compound urinary acidifiers, urinary tract bearberry
only in alkaline urine. cranberry juice antibacterial, uva-ursi
__________________________________ ______________ astringent, (arctostaphylo
ed drug effect diuretics diuretic s uva-ursi)
__________________________________ ______________
d gastrointestinal irritation nsaids

ects hypothalamus-pituitary system, estrogens, hot flashes, black cohosh

es luteinizing hormone secretion and binds oral premenstrual baneberry,
n receptors contraceptives discomfort bugwort,
rease response to estrogen and squawroot,
______________ dysmenorrheal rattleroot
_________________________________
additive effect antihyperlipidemics (cimicifuga
racemosa)

ong bleeding time anticoagulants, anti- borage

antiplatelet inflammatory, (borago
agents sedative officinalis)
_______________________________
 ______________
sedation
anxiolytics

d risk of bleeding antiplatelet acute post- bromelain

agents operative and (ananas
post- comosus)
traumatic
swelling
al effect drug common herb
indication

reases secretion of catecholamines, monoamine shingles, capsicum

s risk of hypertensive crisis oxidase trigeminal (capsicum
inhibitors and diabetic frutescens, c.
________________________________ ______________ neuralgia annum)
d fibrinolytic activity, may prolong bleeding antiplatelet
agents

se electrolyte imbalance and hypokalemia; cardiac stimulant cascara bitter

entiate drug toxicity glycosides, laxative bark
thiazide diuretics (rhanmus
purshiana,
cascara
sagrada)
ontent in herb may inhibit iron absorption iron
mild sedative, chamomile
__________________________________ ______________ antispasmodi (matricaria
c and recutita)
ntains coumarin constituents; may increase anticoagulants antiseptic
of bleeding agent

s dopaminergic effect, may antagonize drug dopamine menstrual chaste tree

receptor disorders berry (vitex
antagonists (i.e., agnus-castus)
phenothiazines)
ntains coumarin constituents; possible anticoagulants,
drug effect antiplatelet menstrual dong quai
agents disorders (angelica
__________________________________h _____________ polymorpha,
ains phytoestrogens; may result in estrogen estrogens a.dahurica,
a.atropurpurea)

m use: stimulates the immune system cold, flu echinacea

yte production stimulated), counteracts drug immunosuppressa (echinacea
hronic use (>6-8 wk): immunosuppressive, nts augustifolia,
 s drug effect. e.pallida)
__________________________________ ____________

d risk of hepatotoxicity drugs that can

damage the liver
e.g. amiodarone,
anabolic steroids,
ketoconazole,
methotrexate

al effect drug common herb

indication

d risk of seizures in patients taking drug phenothiazines, lower serum evening

o lower seizure threshold anticonvulsants cholesterol, primrose
atopic (oenothera
eczema biennis)

anticoagulant, antiplatelet effects; increased anticoagulants migraine, feverfew

eeding antiplatelet fever, (tanacetum
agents menstrual parthenium)
__________________________________ ______________ problems

ed herbal effect nsaids

__________________________________ ______________

ontent in herb may inhibit iron absorption iron

platelet aggregation; additive anticoagulant, anticoagulants hyperlipidemia garlic (allium

let effects antiplatelet sativum)
agents
__________________________________ ______________
entiate drug effect causing hypoglycemia
hypoglycemic
drugs

ease risk of bleeding anticoagulants ginger

platelet aggregation, may have additive anticoagulants varicose ginkgo

ulant, antiplatelet effects antiplatelet veins, (ginkgo biloba)
agents intermittent
______________________________ ______________ claudication,
dementia,
ease risk of seizures, decrease drug effect anticonvulsants vertigo,
__________________________________ ______________ tinnitus, ssri-
d risk of seizure tricyclic induced
antidepressants, sexual
other drugs that dysfunction,
decrease seizure cerebral
threshold vascular
__________________________________ ______________ insufficiency
ay intensify the effects of these drugs & monoamine
the risk of side effects e.g. headache, oxidase inhibitors
& manic episodes (maois)
al effect drug common herb
indication

s hypoglycemic effect hypoglycemic normalize the ginseng

drugs. body, and asian ginseng
___________________________ ______________ provide (panax
ed diuretic effect furosemide resistance to ginseng,
__________________________________ ______________ stress p.quinquefoliu
ease serum digoxin concentrations digoxin m)
__________________________________ ______________
e, visual hallucination, tremor, manic monoamine
s oxidase
inhibitors
__________________________________ ______________
ease risk of bleeding anticoagulants,
antiplatelet
agents
________________________________ ______________
drug effects (herb may intensify side effects) estrogens,
corticosteroids
__________________________________ ______________
ntains estrone, estradiol, estriol; has additive drugs that cause
nic effects gynecomastia
(e.g., calcium
channel blockers,
cardiac
glycosides,
methyldopa,
phenothiazines,
spironolactone)
_________________________________ ______________
may reduce the effectiveness of opioids opioids
berberine; inhibits anticoagulant effects & anticoagulants mucosal goldenseal
 ease risk of blood clots inflammation, (hydrastis
gastritis canadensis)

e hypokalemia diuretics male gossypol

__________________________________ ______________ contraceptive
d gastrointestinal irritation nsaids

platelet aggregation, increases risk of anticoagulants cns stimulant, guarana

potentiate (paullinia
analgesics cupana)

al effect drug common herb

indication

e of herb causes hypotension antihypertensives heart hawthorn

__________________________________ disease, (crataegus
es drug effect ______________ sleep laevigata,
digoxin disorders c.monogyna,
angina c.pinnatifida)

additive sedation anxiolytics, insomnia hops

alcohol (humulus
lupulus l)

ntains coumarin-like constituent; may anticoagulants varicose horse

risk of bleeding veins, other chestnut
venous (aesculus
insufficiencies hippocastanum)

es drug effect hypoglycemic diabetes karela

drugs mellitus bitter melon

sedative effects alcohol, sleep kava-kava

benzodiazepines, disorders, (piper
cns depressants anxiety methylsticum)

ntains iodine, may interfere with thyroid thyroid hormones thyroid kelp
ment dysfunction (laminaria
hyperborea)

ntains caffeine, potential additive cns theophylline, use in

on guarana beverages for kolanut
caffeine caffeine cola, kola
content (cola nitida)

es cns depression cns depressants insomnia, lemon balm

__________________________________ ______________ anxiety (melissa
thyroid hormones officinalis l)
d thyrotropin and interferes with therapy

al effect drug common herb

indication
sm of diuretic effect (increases production spironolactone expectorant, licorice
erone) peptic ulcers (glycyrrhiza
__________________________________ _____________ glabra)
se hypokalemia; may potentiate digoxin cardiac
glycosides,
thiazide diuretics
__________________________________
s immunostimulating effect; may decrease ______________
e to the drugs corticosteroids,
__________________________________ cyclosporine
ease salt & water retention, making ______________
rtensives less effective antihypertensives
__________________________________
ntains sympathomimetic amines, increased ______________
ypertensive crisis monoamine
oxidase inhibitors

d sympathomimetic action; may induce oxytocin, asthma, ma huang

nsion, cns stimulation methyldopa, b- weight loss ephedra,
blockers, squaw tea,
caffeine, mormon tea,
monoamine popotillo, sea
oxidase grape
inhibitors, (ephedra
theophylline, species)
sympathomimetics,
st.john's wort,
guanethidine,
cardiac
 glycosides

nsify the effects of these drugs, causing an hypoglycemic acute & milk thistle
e decrease in blood sugar levels drugs chronic viral (silybum
__________________________________ ______________ hepatitis, marianum)
es blood levels of saquinavir, making it less saquinavir alcoholic
hepatitis

e dose may increase risk of bleeding anticoagulants anxiety, passionflower

restlessness (passiflora
incarnata)

entiate drug effects anticoagulants antineoplastic pau d'arco

taheebo,
trumpet bush
(lapacho
colorado)
al effect drug common herb
indication

ed intestinal drug absorption lithium, digoxin bulk-forming psyllium

__________________________________ ______________ laxative, plantago,
irritable bowel plantain
additive effects antihyperlipidemics syndrome, (plantago
__________________________________ cholesterol species)
______________ lowering
ntains vitamin k;
rfere with anticoagulant therapy anticoagulants

ntains coumarin; large amount may increase anticoagulants red clover

eeding (trifolium
pratense)

d absorption of digitalis and bismuth digitalis, bismuth diuretic sarsaparilla

__________________________________ ______________ honduras
(smilax
cyp450 enzymes; increases drug drugs species)
on metabolized by
cyp450 enzymes
ontent of herb may limit iron absorption iron benign saw palmetto
__________________________________ ______________ prostatic sabal,
hyperplasia cabbage palm
additive effects estrogens (serenoa
repens)

use may cause hypokalemia and potentiate digitalis, diuretics constipation senna (cassia
city acutifolia,
c.augustifolia,
senna
alexadrina)

drug concentrations and half-life; phenytoin shankapulshp

ed drug effect i (ayurvedic
preparation)

al effect drug common herb

indication
siberian
rfere with drug level assay digitalis improve ginseng
endurance (eleutherococc
us, senticosus)

depression st.john's wort

y have monoamine oxidase inhibitor or antidepressants (hypericum
e serotonin reuptake inhibitor effects; (maoi; ssri), perforatum)
hypertensive crisis, serotonin syndromes sympathomimetic
amines,
ma huang,
pseudoephedrine
, yohimbine
__________________________________ ______________

m extract may reduce peak and trough digoxin

concentrations
______________
__________________________________
iron
ontent of herb may limit iron absorption ______________
__________________________________
photosensitizers
d risk of photosensitivity, avoid use with uv e.g. piroxicam,
 apy omeprazole,
lansoprazole,
sulfonamides
__________________________________ ______________

uce blood levels of indinavir making it less indinavir

______________
_________________________________
cyclosporine
uce blood levels of cyclosporine making it ______________
ctive
_________________________________
warfarin
uce blood levels of warfarin making it less ______________

__________________________________ benzodiazepines
uce the effectiveness of these drugs in
anxiety and may increase the risk of side
uch as drowsiness

al effect drug common herb

indication

ntains curcumin; may potentiate antiplatelet antiplatelet dyspepsia turmeric

agents tumeric, indian
saffron
(curcuma
longa)

digoxin-like cardiac effects digoxin diarrhea uzara root

(uzarae radix)

sedation opiates, alcohol, anxiolytics valerian

barbiturates, (valeriana
cns depressants officinalis)

er seizure threshold anticonvulsants loss of wormwood

appetite,
dyspepsia

yohimbe
s α2-antagonist activity antihypertensives impotence yohimbine
ce hypotension or hypertension, , caffeine, (pausinystalia
dia. ephedrine, ma yohimbe)
huang
__________________________________ ______________
e monoamine oxidase inhibitor activity antidepressants,
st. john's wort

e bleeding anticoagulants anti-oxidant,

__________________________________ ______________ anti- pycnogenol/
s with their action cholesterol inflammatory grape seed
lowering drugs
y juice has a moderately high concentration
e, a common component of kidney stones, urinary tract cranberry
uld be limited in patients with a history of infections,
hiasis acidifies urine

botanical supplements and some associated risks

comments toxic agents. intended use commercial name,

effects scientific name,
plant parts
comfrey
avoid internal ingestion: pyrrolizidine internal digestive symphytum species
topical use should be alkaloids, aid, topical for leaves and roots
limited to 4-6 weeks hepatotoxicity wound healing

avoid ingestion of any pyrrolizidine upper respiratory coltsfoot

parts of plant; leaves alkaloids, tract infections tussilago farfara
may be used topically hepatotoxicity leaves, flower
for anti-inflammatory
effects for up to 4-6
weeks

avoid hepatotoxicity diet aid germander

teucrium
chamaedrys
leaves,tops
avoid pyrrolizidine anti-inflammatory, borage
alkaloids, diuretic borago officinalis
hepatotoxicity tops, leaves

avoid hepatotoxicity anti-infective, chaparral

antioxidant, larrea tridentata
anticancer twigs, leaves

avoid safrole oil, blood thinner sassafras

hepatocarcinogen in sassafras albidum
animals root bark

avoid alkaloid, cardiac and analgesic aconite

central nervous aconitum species
system effects

pennyroyal
avoid pulegone and digestive aid, mentha pulegium or
pulegone induction of hedeoma pulegioides
metabolite, liver menstrual flow, extract
failure, renal failure abortifacient
comments toxic agents. intended use commercial name,
effects scientific name,
plant parts

avoid hemorrhagic anti rheumatic poke root

gastritis phytolacca
americana

avoid hepatotoxicity analgesic; jin bu huan

sedative

avoid in patients at risk central nervous diet aid; ephedra, ma huang

for stroke, myocardial system toxicity, stimulant; ephedra species
infarction, uncontrolled cardiac toxicity bronchodilator
blood pressure,
seizures, general
anxiety disorder
avoid in patients with bronchospasm, tonic royal jelly
chronic allergies or anaphylaxis apis mellifera
respiratory diseases; (honeybee)
asthma, chronic
obstructive pulmonary
disease, emphysema,
atopy

food & drug interactions

1medicines can treat and cure many health problems. however, they must
be taken properly to ensure that they are safe and effective. many
medicines have powerful ingredients that interact with the human
body in different ways, and diet and lifestyle can sometimes have a
significant impact on a drug's ability to work in the body.

2certain foods, beverages, alcohol, caffeine, and even cigarettes can

interact with medicines. this may make them less effective or may
cause dangerous side effects or other problems.

3changes in a medicine's effect due to an interaction with food, alcohol or

caffeine can be significant; however, there are many individual factors
that influence the potential for such variations, like dose, age, weight,
sex, and overall health.

this brochure has information about possible interactions between many

medications with food, alcohol and caffeine. it is also important to remember
that many drugs interact with other drugs and may cause serious medical
conditions.

allergies
antihistamines are used to relieve or prevent the symptoms of colds, hay
fever, and allergies. they limit or block histamine, which is released by the
body when a patient gets exposed to substances that cause allergic reactions.
these products vary in their ability to cause drowsiness and sleepiness.

antihistamines

1some examples are:

brompheniramine, chlorpheniramine, diphenhydramine, fexofenadine,

loratadine, cetirizine

2interaction
1. food: it is best to take antihistamines (especially second
generation) on an empty stomach to increase their effectiveness.

2. alcohol: some antihistamines may increase drowsiness and slow mental

and motor performance. operating machinery or driving should be done
cautiously.

arthritis and pain

analgesic / antipyretic
they treat mild to moderate pain and fever.

3an example is: acetaminophen (paracetamol)

4interactions
1. food: for rapid pain relief, the drug can be taken on an empty
stomach because food may slow the body's absorption of
acetaminophen.

2. alcohol: avoid or limit the use of alcohol because chronic alcohol use can
increase the risk of liver damage or stomach bleeding.

non-steroidal anti-inflammatory drugs (nsaids)

1nsaids reduce pain, fever, and inflammation.

2some examples are: aspirin, ibuprofen, naproxen, ketoprofen.

3interaction
1. food: because these medications can irritate the stomach, they
are best taken with food or milk.

2. alcohol: avoid or limit the use of alcohol because chronic alcohol use can
increase the risk of liver damage or stomach bleeding.

3. buffered aspirin or enteric coated aspirin may be preferable to regular

aspirin to decrease stomach bleeding.

corticosteroids

1they are used to provide relief to inflamed areas of the body.

corticosteroids reduce swelling and itching, and help relieve allergic,
rheumatoid, and other conditions.

2some examples are: methylprednisolone, prednisone, prednisolone

3interaction
1. food: take with food or milk to decrease stomach upset.

narcotic analgesics

1narcotic analgesics are available only with a prescription. they provide

relief for moderate to severe pain. codeine can also be used to
suppress cough. some of these medications can be found in
combination with non-narcotic drugs such as cough syrups.

2these medications should be taken very cautiously because they may be

habit forming and can cause serious side effects when used
 improperly.

3some examples are: codeine, morphine, oxycodone, meperidine.

4interaction

1. alcohol: avoid alcohol because it increases the sedative effects of the

medications.

asthma

bronchodilators

1bronchodilators are used to treat the symptoms of bronchial asthma,

chronic bronchitis and emphysema. these medicines open air passages
to the lungs to relieve wheezing, shortness of breath and troubled
breathing.

2some examples are: theophylline, albuterol (salbutamol), epinephrine

(adrenaline)

3interactions

1. food: the effect of food on theophylline medications can vary widely.

high-fat meals may increase the amount of theophylline in the body, while
high-carbohydrate meals may decrease it.

it is important to check with the pharmacist about which form is taken

because food can have different effects depending on the dosage form (e.g.,
regular release, sustained release).

2. caffeine: avoid large amounts of foods and beverages that contain caffeine
(e.g., chocolate, colas, coffee, tea) because both oral bronchodilators and
caffeine stimulate the central nervous system.

3. alcohol: avoid alcohol with theophylline medications because it can

increase the risk of side effects such as nausea, vomiting, headache and
irritability.

cardiovascular disorders
1there are numerous medications used to treat cardiovascular disorders
such as high blood pressure, angina, arrhythmias, and high
cholesterol.

2these drugs are often used in combination to enhance their effectiveness.

some classes of drugs can treat several conditions. for example, beta
blockers can be used to treat high blood pressure, angina, and
arrhythmias.

3some of the major cardiovascular drug classes are:

diuretics

1diuretics help eliminate water, sodium, and chloride from the body.

2there are different types of diuretics.

some examples are: furosemide, hydrochlorothiazide, triamterene,

triamterene + hydrochlorothiazide, bumetamide, metolazone.

1interaction

1. food: diuretics vary in their interactions with food and specific nutrients.

a. some diuretics cause loss of potassium, calcium, and magnesium e.g.

furosemide.

b. triamterene, on the other hand, is known as a "potassium-sparing"

diuretic. it blocks the kidneys’ excretion of potassium, which can cause
hyperkalemia. excess potassium may result in irregular heartbeat and heart
palpitations. with triamterene, avoid large amounts of potassium-rich foods
such as bananas, oranges and green leafy vegetables, or salt substitutes that
contain potassium.

beta blockers

2beta blockers decrease the nerve impulses to the heart and blood vessels.
 this decreases the heart rate and the work load of the heart.

3some examples are: atenolol, metoprolol, propranolol, nadolol.

4interaction

1. alcohol: avoid alcohol with propranolol because the combination lowers

blood pressure too much.

nitrates

1nitrates relax blood vessels and lower the demand for oxygen by the
heart.

2some examples are: isosorbide dinitrate, nitroglycerin.

3interaction

1. alcohol: avoid alcohol because it may add to the blood vessel-relaxing

effect of nitrates and result in dangerously low blood pressure.

angiotensin converting enzyme (ace) inhibitors

1ace inhibitors relax blood vessels by preventing angiotensin ii, a

vasoconstrictor, from being formed.

2some examples are: captopril, enalapril, lisinopril

 3interactions

1. food:

a. food can decrease the absorption of captopril. so captopril should be taken

one hour before or two hours after meals.

b. ace inhibitors may increase the amount of potassium in the body. so avoid
large amounts of foods high in potassium such as bananas, green-leafy
vegetables, and oranges.

hmg-coa reductase inhibitors

1otherwise known as "statins," these medications are used to lower

cholesterol. they work to reduce the rate of production of ldl
cholesterol.

2some of these drugs also lower triglycerides.

3recent studies have shown that pravastatin can reduce the risk of heart
attack, stroke, or miniature stroke in certain patients.

4some examples are: atorvastatin, cerivastatin, fluvastatin, lovastatin,

pravastatin, simvastatin.

5interaction

1. alcohol: avoid drinking large amounts of alcohol because it may increase

the risk of liver damage.
2. food: lovastatin should be taken with the meals to enhance absorption.

anticoagulants

1anticoagulants help to prevent the formation of blood clots.

2an example is: warfarin

3interactions

1. food:

a. vitamin k reduces the effectiveness of anticoagulants. so limit the amount

of foods high in vitamin k (such as broccoli, spinach, kale, turnip greens,
cauliflower, and brussel sprouts).

b. high doses of vitamin e (400 iu or more) may prolong clotting time and
increase the risk of bleeding.

infections

antibiotics and antifungals

1many different types of drugs are used to treat infections caused by

bacteria and fungi.

2some general advice for the patient when taking any such product is:

1. consult the doctor about any skin rashes that might appear while taking
antibiotics. a rash can be a symptom of an allergic reaction, and allergic
reactions can be very serious.
2. consult the doctor if diarrhea occurs.

3. if using birth control, consult the health care provider because some
methods may not work when taken with antibiotics.

4. finish all the medication even after feeling better.

5. take with plenty of water.

antibacterials
penicillin

1some examples are: penicillin v, amoxicillin, ampicillin

2interaction

1. food: taken on an empty stomach, but if it upsets the stomach, taken with
food.

cephalosporins

1some examples are: cefaclor, cefadroxil, cefixime, cefprozil, cephalexin.

2interaction

1. food: taken on an empty stomach one hour before or two hours after
meals. if stomach gets upset → drug taken with food.

quinolones

1some examples are: ciprofloxacin, levofloxacin, ofloxacin,

trovafloxacin.
 2interactions

food:

1. taken on an empty stomach one hour before or two hours after meals. if
stomach gets upset, medication is taken with food.

2. calcium-containing products like milk, yogurt, vitamins or minerals

containing iron, and antacids should be avoided because they significantly
decrease drug concentration.

3. caffeine: taking these medications with caffeine- containing products

(e.g., coffee, colas, tea, and chocolate) may increase caffeine levels, leading
to excitability and nervousness.

macrolides

1some examples are: azithromycin, clarithromycin, erythromycin

erythromycin + sulfisoxazole (pediazole)

2interaction

1. food: taken on an empty stomach one hour before or two hours after
meals. if stomach gets upset → drug taken with food.

sulfonamides
 1an example is: sulfamethoxazole + trimethoprim (bactrim)

2interaction

1. food: taken on an empty stomach one hour before or two hours after
meals. if stomach gets upset → drug taken with food.

tetracyclines

1some examples are: tetracycline, doxycycline, minocycline

2interaction

1. food:

a. taken on an empty stomach one hour before or two hours after meals. if
stomach gets upset → drug taken with food.

b. however, it is important to avoid taking tetracycline with dairy products,

antacids and vitamins containing iron because these can interfere with the
medication's effectiveness.

nitroimidazole

1an example is: metronidazole (flagyl)

2interaction

1. alcohol:

patient should avoid drinking alcohol or using medications that contain

alcohol or eating foods prepared with alcohol while taking metronidazole
and for at least three days after finishing the medication. alcohol may cause
nausea, abdominal cramps, vomiting, headaches, and flushing (disulfiram-
like action of the drug).

antifungals

1some examples are: fluconazole, griseofulvin, ketoconazole,

itraconazole

2interaction

1. food:

a. these medications should not be administered with dairy products (milk,

cheeses, yogurt, ice cream).

b. these medications should not be administered with antacids; since acidic

medium is essential for the dissolution of these drugs.

2. alcohol: patient should avoid drinking alcohol, using medications that

contain alcohol, or eating foods prepared with alcohol while taking
ketoconazole and for at least three days finishing the medication.

mood disorders
depression, emotional, and anxiety disorders

1depression, panic disorder and anxiety are a few examples of mood

disorders — complex medical conditions with varying degrees of
severity.
 2when using medications to treat mood disorders it is important to
instruct the patient to take the medication as directed even if he feels
better. in some cases it may take several weeks for an improvement in
symptoms to occur.

monoamine oxidase (mao) inhibitors

1some examples are: phenelzine, tranylcypromine

2interactions

1. mao inhibitors have many dietary restrictions, and people taking them
need to follow the dietary guidelines and physician's instructions very
carefully. a rapid, potentially fatal increase in blood pressure can occur if
foods or alcoholic beverages containing tyramine are consumed while taking
mao inhibitors.

2. alcohol: should be avoided.

3. food: foods high in tyramine that should be avoided include:

1. processed, cheddar, blue, brie, mozzarella and parmesan cheese; yogurt,

sour cream.

2. beef or chicken liver; cured meats such as sausage and salami; caviar;
dried fish.

3. avocados, bananas, yeast extracts, raisins, sauerkraut, soy sauce, miso

soup.
4. broad (fava) beans, ginseng, caffeine-containing products (colas,
chocolate, coffee and tea).

anti-anxiety drugs

1some examples are: lorazepam, diazepam, alprazolam

2interaction

1. alcohol: may impair mental and motor performance (e.g., driving,

operating machinery).

2. caffeine: may cause excitability, nervousness, and hyperactivity and

lessen the anti-anxiety effects of the drugs.

antidepressant drugs

1some examples are: paroxetine, sertraline, fluoxetine.

2interactions

1. alcohol: although alcohol may not significantly interact with these drugs
to affect mental or motor skills, people who are depressed should not drink
alcohol.

2. food: these medications can be taken with or without food.

stomach conditions
conditions like acid reflux, heartburn, acid indigestion, sour stomach, and
gas are very common ailments. the goal of treatment is to relieve pain,
promote healing and prevent the irritation from returning. this is achieved by
either reducing the acid the body creates or protecting the stomach from the
acid. lifestyle and dietary habits can play a large role in the symptoms of
these conditions. for example, smoking cigarettes and consuming products
that contain caffeine may make symptoms return.

histamine blockers

1some examples are: cimetidine, famotidine, ranitidine, nizatadine.

2interactions

1. alcohol: avoid alcohol while taking these products. alcohol may irritate
the stomach and make it more difficult for the stomach to heal.

2. food: can be taken with or without regard to meals.

3. caffeine: caffeine products (e.g., cola, chocolate, tea and coffee) may
irritate the stomach.

grape fruit juice & drugs

is there a role for grape fruit juice in therapeutics?
1this is a very interesting question. in the usa there are anecdotal reports
of patients being counseled to take their medications with grapefruit
 juice (gj) to boost the blood levels of the medication.

2while this may be appropriate in specific clinical situations, health care

professionals should not routinely counsel patients to use gj to
increase the blood levels and effects of their medication.

3the most reasonable guideline for health care professionals to follow is

to counsel patients that if they are not currently taking their
medications with gj regularly, don’t start. if they are already taking
their medications with gj regularly, don’t stop.

4if this interaction is to ever be used therapeutically, it could be with

drugs that undergo complete first-pass metabolism, and are therefore
only active by the intravenous route. also, drug which undergo
incomplete first-pass metabolism could be co-administered with gj to
produce more consistent bioavailability and clinical response.

5it is advisable not to consume grapefruit or grapefruit juice while taking

medications used to treat anxiety, depression, high blood pressure,
hiv/aids, cancer, irregular heart rhythms, infections, psychotic
problems, erectile dysfunction, angina, convulsions, gastrointestinal
reflux, high cholesterol, or organ graft rejections due to the risk of
potentially serious interference with blood drug levels.

basic mechanism of action

drugs that interact with grapefruit juice (gj) undergo cytochrome p450
oxidative metabolism in the intestinal wall or liver. gj contains various
bioflavonoids which have been demonstrated to affect the cytochrome
p450(cyp) system (especially at isoenzymes cyp1a2, and cyp3a4) by binding
to the isoenzyme as a substrate and impairing first-pass metabolism, either
by direct inactivation or inhibition of the enzyme.

the net effect on the cyp enzymes from this inhibition seems to be a selective
down-regulation of cyp3a4 in the small intestine.

naringin

naringin is the main bioflavonoid in gj. naringin is not a potent cyp

inhibitor, but is partially metabolized by enteral bacteria to naringenin,
which is a potent inhibitor of p450 enzymes, and was originally thought to
be the component of gj responsible for the interactions, although it was
thought possible that another unidentified component in grapefruit may also
have been responsible, since giving naringin alone does not seem to cause
the same degree of inhibition as gj.

furanocoumarins/bergamottin

1researchers have isolated a group of compounds from gj called

furanocoumarins, which appear to be specific cyp3a4 inhibitors.

2further in vito studies determined that several compounds found in gj

inhibit cyp3a4 enzymes. specifically, these were nootkanone (a
sesquiterpene), and 4 derivatives of coumarin, geranyloxycoumarin,
bergamottin, and 2 chemical with very long technical names, denoted
as gf-i-1 and 4.

3results of confirmatory in vivo testing of cyp3a4 inhibition with

 externally administered gf-i-1 and gf-i-4 have shown that wide inter-
individual variability in response to these interactions is present.

p-glycoprotein

1studies on gj have revealed that it significantly activates p-glycoprotein

mediated reduction in bioavailability, partially counteracting the
cyp3a4 inhibitory effects of gj. this may explain why the effect of gj
on drug absorption is unpredictable and highly variable.

2p-glycoprotein is an efflux pump that, like cyp3a enzymes, is located at

high levels in intestinal enterocytes, the primary site of oral
absorption, where it actively secretes absorbed drug back into the gut
lumen.

3drugs studied included vinblastine, cyclosporine, digoxin (lanoxin),

fexofenadine (allegra) and losartan (cozaar) (as cyp3a and/or p-
glycoprotein substrates) as well as felodipine (plendil, renedil) and
nifedipine (adalat, procardia) (primarily cyp3a substrates):

1. the efflux of vinblastine, cyclosporine, digoxin, fexofenadine

and losartan were increased in the presence of gj, while no
increased efflux of nifedipine and felodipine was noticed when
gj was added.

2. it should be emphasized that this experiment was performed in

laboratory cell cultures, and is not a human trial, but it does
point the way for further studies on p-glycoprotein effects
observed in this study.

3. the actual effects of gj on absorption of drugs not studied in

 humans (vinblastine (not given orally), digoxin, fexofenadine
and losartan) are unknown.

confirmation of effect of raw grapefruit and extract

• studies confirmed that the activity of grapefruit segments and an

extract of the peel and rind had similar drug interaction potential to
the juice.

• it was concluded if there is a concern for a drug interaction with gj, it

seems logical to avoid consumption of grapefruit segments as well
during pharmacotherapy with the affected drug(s).

• confectioneries, like marmalades, made from grapefruit peel may also

cause a drug interaction

examples of drugs interacting with gj

gj drug interactions (dis) with non-sedating antihistamines:
* desloratadine (clarinex)

desloratidine does not undergo primary metabolism via cyp 3a4, and is not a
p-glycoprotein substrate, ∴gj intake produces no changes in qtc intervals on
the ecg & does not affect the rate or extent of desloratidine absorption.

* fexofenadine (allegra)
bioavailability and peak serum concentration were decreased while no
changes in qtc intervals on the ecg were noted in any patient receiving
fexofenadine and gj. this is unexpected since fexofenadine does not undergo
significant biotransformation by cyp enzymes. however, co-administration
of fexofenadine with ketoconazole and erythromycin, which as known cyp
3a4 inhibitors, resulted in significant increases in the extent of absorption of
fexofenadine. (ketoconazole and erythromycin have since been shown to
inhibit p-glycoprotein).

this built on a study, which suggested that fexofenadine may be a substrate

for organic anion transporting polypeptide (oatp), another transporter
system, and that grapefruit, and possibly orange, apple, and grape juices may
also affect disposition of fexofenadine through effects on oatp.

this study provided support for a new model of food-drug interaction, that
includes the role of oatp, as well as cyp 3a4, and p-glycoprotein.

gj drug interactions (dis) with anti-infectives:

* albendazole (albenza)

albendazole is an anthelminthic drug used for the treatment of intestinal

parasites (eg. ascaris). albendazole has poor absorption but this can be
increased by taking the medication with a fatty meal. albendazole is rapidly
converted to its active metabolite albendazole sulfoxide, by cyp 3a4
enzymes in the intestine and liver.

gj causes an increase in peak serum concentration & in bioavailability of

albendazole.

albendazole half-life is decreased & time to peak concentration is prolonged

by gj, an unexpected finding.
* praziquantel

praziquantel has a generally low and variable bioavailability. gj increases the

bioavailability & peak serum concentration of the drug while elimination
half-life and time to peak level are not significantly affected. the joint
administration of praziquantel and gj could lead to a further improvement in
the effectiveness of praziquantel therapy.

* clarithromycin (biaxin)

administration of gj increases the time to peak concentration of

clarithromycin and its 14-hydroxy metabolite, but does not otherwise affect
pharmacokinetic parameters.

clarithromycin can safely be consumed with gj without concern that the

drugs antimicrobial activity may be altered, due to a pharmacokinetic
interaction.

* erythromycin (erythrocin)

gj slightly increases the bioavailability & peak serum concentration of

erythromycin, but not to a beneficial level, since high antibiotic levels are
desired for treatment of susceptible infections. half-life and time to peak
concentration are not affected.

* indinavir (crixivan)

peak serum concentration & bioavailability of the drug are decreased by gj.
time to peak blood level is increased. however, concomitant administration
of gj with indinavir in hiv-infected subjects is not associated with uniform
changes in indinavir bioavailability.

* saquinavir
gj increases the bioavailability & the peak serum concentration of the drug.

some studies concluded that for most patients, ingestion of saquinavir with
gj results in an increase in drug exposure similar to that expected after
doubling the dose.

the in vivo effects of grapefruit juice co-administration are most likely the
result of effects of cyp 3a4 (inhibition and down regulation) and only to a
minor extent on modulation of p-glycoprotein function.

in contrast to saquinavir, there is a decrease in the bioavailability of

indinavir occuring with the concurrent administration of gj. the effects of gj
on the disposition of ritonavir have not been reported.

physicians should be aware of the difference in interactions between gj,

saquinavir and indinavir.

* itraconazole (sporanox)

itraconazole is an antifungal agent, often used for treatment of fungal

infections resistant to other drugs, such as ketoconazole and fluconazole.

gj has no significant effect on any pharmacokinetic parameter of

itraconazole. interestingly, orange juice significantly decreases half-life and
bioavailability of itraconazole.

gj drug interactions (dis) with benzodiazepines:

* alprazolam (xanax)

gj does not significantly increase the drug bioavailability and the peak serum
concentration. alprazolam has a high oral bioavailability, which suggests
that it has a lower rate of first-pass metabolism, in contrast to triazolam. this
explains the greater sensitivity to gj interaction for triazolam. this suggests
that an interaction between gj and alprazolam does not need to be considered
in the clinical situation.

* diazepam (valium)

gj increases the bioavailability & the peak serum concentration of diazepam.

it also postpones the time to reach peak concentration of diazepam.

* triazolam

gj increases the bioavailability & the peak concentration of triazolam.

drowsiness therefore could be increased when triazolam is given
concurrently with gj.

this could have resulted from inhibition of triazolam metabolism during the
elimination phase due to inhibition of hepatic cyp 3a4 activity.

the importance of these interactions is evident in patients with other

conditions that might increase benzodiazepine bioavailability (e.g. advanced
age, liver cirrhosis, concurrent use of other medications that inhibit
cytochrome p450). these patients should be observed for increased sedation.

n.b. physicians may consider counselling selected patients to avoid

concurrent consumption of triazolam or diazepam and gj. injectable
midazolam, will not be affected by gj. evidence now indicates alprazolam is
safe with gj.

gj drug interactions (dis) with calcium-channel blockers (ccbs):

* amlodipine (norvasc), felodipine (plendil), nifedipine (adalat)

the grapefruit juice-drug interaction seems to affect mainly the

dihydropyridine family of calcium-channel blockers.

tachycardia and decreased diastolic blood pressure were noted when

felodipine was given with gj hypertensive patients. gj increases the
bioavailability & hence the side effects (facial flushing, headache, dizziness)
of felodipine. grapefruit segments and an extract of the peel and rind also
increase the drug's bioavailability

gj increases the bioavailability of nifedipine & amlodipine.

it seems logical to avoid consumption of grapefruit during pharmacotherapy

with the affected drug(s).

a clinical case report described gj intake resulting in marked hypotension in

a patient with renovascular hypertension taking large doses of nifedipine for
blood pressure control.

* diltiazem (cardizem)

bioavailability & peak serum concentration of diltiazem are not affected by

gj.

* nimodipine (nimotop)

gj increases the bioavailability & the peak serum concentration of the drug.
it also prolongs the time to peak concentration. since gj intake may
contribute to the variability of nimodipine pharmacokinetics, the interaction
should be avoided.

* nitredipine

there is a marked inter-individual variability in the magnitude of the

interaction.

* verapamil (isoptin)

gj has no significant effect on verapamil pharmacokinetic parameters.

n.b.

1) in most studies, the interactions were tested in healthy subjects. this is an

important distinction, as patients with hypertension or other cardiac
conditions may experience more pronounced effects on heart rate and blood
pressure.

2) gj can cause substantial increases in bioavailability of certain calcium-

channel blockers, primarily the dihydropyridine type. patients receiving
these medications and drinking grapefruit juice regularly should be
monitored for increased response. a reasonable guideline for health care
professionals is to tell patients that if they are not currently taking their
antihypertensive medications with grapefruit juice regularly, don’t start. if
they are already taking their medications with grapefruit juice regularly,
and are not experiencing adverse effects, don’t stop.

gj drug interactions (dis) with cholesterol-lowering drugs:

hmg-coa reductase inhibitors ("-statins")

* lovastatin (mevacor)

gj increases the peak concentrations & the bioavailability of lovastatin, it

does not affect the half-life. it is advisable not to co-administer lovastatin
with grapefruit.

* simvastatin (zocor)

gj increases the bioavailability, the peak serum concentration & the time to
peak concentration of simvastatin. it is recommend that concomitant use of
grapefruit juice and simvastatin should be avoided, or the dosage of
simvastatin should be greatly reduced.

* atorvastatin (lipitor)

gj increases the bioavailability of atorvastatin. it does not affect the peak

concentration, but increases the time to peak concentration and half-life.
atorvastatin has two active metabolites: atorvastatin lactone and 2-
hydroxyatorvastatin acid which are also affected by gj. atorvastatin kinetics
are affected to a considerably smaller degree with lovastatin and simvastatin.

it is advisable that grapefruit juice, at least in large amounts, should not be

used concomitantly with atorvastatin, or the dosage of atorvastatin should be
reduced accordingly.

* pravastatin (pravachol)

gj has no significant effects on the pharmacokinetics of pravastatin, other

than the time to peak concentration of the drug which is significantly
prolonged with co-administration of gj. pravastatin is hydrophilic with an
oral bioavailability of approximately 20%, and is excreted to a significant
extent unchanged in the urine. cyp3a4 plays only a minor role in the
metabolism of pravastatin, which explains why pravastatin is not susceptible
to interaction with gj and other cyp3a4 inhibitors.

* fluvastatin (lescol)

there are no significant interactions between gj and fluvastatin. fluvastatin is

predominantly metabolized by cyp2c9. it is not metabolized to a significant
extent by other cytochrome subclasses, including cyp3a4. however, since
fluvastatin demonstrates a moderate affinity for the cyp 3a4 isoenzyme,
drugs or agents such as gj that inhibit this enzyme...may represent a
potential, at least in some patients, for drug interactions when combined
with fluvastatin.

gj drug interactions (dis) with psychiatric medications:

* buspirone (buspar)

gj increases the bioavailability & the peak serum concentration of the

drug. it also leads to the prolongation of the time to peak concentration & an
increase in the drug's half-life. more incidence of side effects (including
dizziness, nausea, drowsiness and tingling) could occur with co-
administration of gj.

although buspirone has a relatively wide therapeutic index, concomitant use

of at least large amounts of grapefruit juice with buspirone should be
avoided.

* carbamazepine (tegretol)

bioavailability of carbamazepine increases with gj, the peak and trough

carbamazepine concentrations also increase. clinicians should instruct
patients receiving carbamazepine to avoid consumption of grapefruits to
avoid undue adverse effects. carbamazepine has a narrow therapeutic index,
and if toxicity is suspected or confirmed by serum level monitoring, the
patient should be questioned about gj intake.

* clomipramine (anafranil)

clomipramine serum levels increase when taken concurrently with gj. the
magnitude of this increase may be sufficient to increase the risk of adverse
effects in some patients.

* clozapine (clozaril)

clozapine is an atypical antipsychotic drug, which is known to be

metabolized via cyp 1a2 and cyp 3a4, to two principal metabolites,
desmethylclozapine, and clozapine-n-oxide. gj does not affect the
bioavailability or the peak serum concentration of either clozapine, or its
metabolites. gj does not alter multiple-dose pharmacokinetics and
pharmacodynamics of clozapine. one reason is that

enzymes other than cyp 3a4 (such as cyp 1a2 and cyp 2c19) mediate
clozapine disposition.

* haloperidol (haldol)

no interaction between the drug & gj, this may be due to the weak specificity
of cyp3a4 as a substrate and the relatively high bioavailability of
haloperidol. gj is probably safe for patients treated with haloperidol.

gj drug interactions (dis) with immunosuppressant:

bioavailability & peak serum concentration increase when cyclosporine
(sandimmune) is given with gj.

adverse effects experienced by subjects receiving the drug with gj were not
reported. gj may be a potentially useful agent to increase cyclosporine
levels.

however, transplant patients shouldn't drink gj while taking cyclosporine,

unless specifically advised to do so by their transplant physician. if an
interaction causing toxicity is suspected, monitoring of cyclosporine trough
levels is recommended.

concerning the interaction between gj and tacrolimus, an

immunosuppressant with similar function and metabolic pathways (cyp 3a4)
to cyclosporine, patients may experience increases in trough level of the
drug. since increased adverse effects correlate with increased trough levels,
 the combination of tacrolimus and gj should be used with caution.

sirolimus (rapamune) is metabolized extensively via cyp3a4 in the gut wall

and liver, and may potentially have interactions with gj, but this potential has
not been scientifically studied.

www.alam-tany.com

a summary of some names of medicinal herbs

in arabic, latin & english

name in arabic latin name english name no

‫الفا الفا صفصفة برسيم حجازي فصة‬ medicago sativa alfalfa
1
‫ صبير –مقر –سولع مخزني‬-‫صبار‬ aloe vera aloe
2
‫حشيشة الم‬ angelica archangelica angelica
3
‫عنب الديب – قلطب زحاف – بقس الص‬
arctostaphylo s uva ursi bearberry uva ursi 4
‫ عيسر‬- ‫– عنب ديب‬
b aneberry bugwort squawroot
‫اقني – عنقودية – قاتل ا‬ black cohosh
rattleroot cimicifuga racemosa 5
‫لسان الثور – حمحم مخزني – ابو الريش‬
borago officinalis borage 6
‫كح‬
‫فلفل شطة – فليفلة – فليفلة حمراء –فل‬ c.fructescens - c.annum
capsicum
‫حريف – فليفلة حادة – فلف رو‬ 7
‫ ن‬-‫عوسج فارس – قلف مقدس – عجرم‬
rhanmus purshiana . cascara
‫بورشيانا )كسكارا( لحاء نوع من انواع‬ sagrada cascara 8
‫اشجار النبق‬
matricaria recutita
‫البابونج اللماني – فراخ ام علي‬ chamomile
9

‫كف مريم – حشيشة ابة شيح – شجرة‬ vitex agnus -castus chaste berry 10

‫الرهبان – كف الجزماء – شجرة ابراهيم‬

 ‫مدعى الحمام – ارثد – سرساد ‪ -‬منجكش‬

‫الخنيسية‬ ‫‪echinacea sp.‬‬ ‫‪echinacea‬‬ ‫‪11‬‬

‫زهرة الربيع المسائية – اخدرية – حشي‬
‫الح‬ ‫‪oenothera biennis‬‬ ‫‪evening primerose‬‬ ‫‪12‬‬
‫غرديب – كافورية – حشيشة الح‬
‫‪tanacetum chrysanthemum‬‬ ‫‪fever few‬‬ ‫‪13‬‬
‫زنج‬
‫‪zingiber officinale‬‬ ‫‪ginger‬‬ ‫‪14‬‬
‫ثوم – ف‬
‫‪allium sativum‬‬ ‫‪garlic‬‬ ‫‪15‬‬
‫الشفتين – شجر معابد‪ -‬جنكة – جينك‬
‫مع‬ ‫‪ginkgo biloba‬‬ ‫‪ginkgo‬‬ ‫‪16‬‬
‫الجنسنج الكورى او الصيني – رن شن‬
‫‪panax ginseng‬‬ ‫‪17‬‬
‫جذر النسان – اراليا – الجنسنج المريكي‬
‫كسي يانع شن – جذر انس‬ ‫‪ginseng‬‬
‫‪p .quiquefolium‬‬
‫حوذان مر – خاتم ذهب ‪ -‬هيدراستو‬
‫‪hydrastis canadensis‬‬ ‫‪golden seal‬‬ ‫‪18‬‬
‫جوا‬
‫‪paullinia cup ana‬‬ ‫‪guarana‬‬ ‫‪19‬‬
‫الزعرور – الشوكة البيضاء – زعرور الد‬ ‫‪crataegus monogyna‬‬ ‫‪hawthorn‬‬
‫‪20‬‬
‫جنجل – حشيشة الدينار – كرمة الشم‬
‫‪humulus lupulus‬‬ ‫‪hops /bine‬‬ ‫‪21‬‬
‫الكستناء الهندي – قسطلة الحصان –‬ ‫‪22‬‬
‫فروة – كستناء الجبل – قندلي – قسط‬ ‫‪aesculus hippocastanum‬‬ ‫‪horse chestnut‬‬
‫هن‬
‫فلفل كاوا – فلفل مسكي – فلف مسك‬ ‫‪23‬‬
‫‪piper methysticum‬‬ ‫‪kava kava‬‬
‫كاوا ك‬
‫‪cola nitida‬‬ ‫‪24‬‬
‫كول – جوز الزلج – جوز السو‬ ‫‪colanut‬‬
‫المليسة – الحبق الترجاني – ترجان – ش‬ ‫‪25‬‬
‫فرنسة – مليسة ترنجان – بقلة ضب‬ ‫‪mellissa officinalis l‬‬
‫‪lemon balm‬‬
‫حشيشة نحل – الحبق القرنفلي – ح‬
‫بربري – باذرنج‬
‫‪glycyrrhiza glabra‬‬ ‫‪26‬‬
‫سوس مجزني – عرقسوس – رب السو‬ ‫‪liquorice‬‬
‫ذيل ماعز – علد – ايفيدرة – عنب بح‬ ‫‪ma haung ephedra‬‬ ‫‪27‬‬
‫‪ephedra alata‬‬
‫علندة – عاذر – جاشية – عدام – عب ال‬
‫‪ephedra distachya ephedra‬‬
‫– عقد مزدوج السنابل – ايفيدرا – جاشي‬
‫‪sinica‬‬
‫عدام – العاذر – علندة – ماهو‬
 ‫حرشيف بري – شوك الجمل – لحل‬ ‫‪silybum marianum‬‬ ‫‪28‬‬
‫‪milk thistle‬‬
‫خرفيش الجمال – عكوب – شكوك الد‬
‫زهرة اللم – زهرة الحزان – زهرة الس‬ ‫‪passiflora incarnata‬‬ ‫‪29‬‬
‫‪passion flower‬‬
‫– المية ارجو‬
‫‪p.ovata‬‬ ‫‪30‬‬
‫زباد – كنباثي – لقمة نعجة – نبات بيضي‬
‫‪p.psyllium‬‬
‫ودنة – انم – مصيص – بزر قطونة – عس‬ ‫‪psyllium plantago‬‬
‫‪p.s£p.‬‬
‫البراغيث – اذنية حمل – قطنية – خزام‬
‫‪trifolium pratense‬‬ ‫‪31‬‬
‫نفل المروج – نفل بنفس‬ ‫‪red clover‬‬
‫‪smilax aspera‬‬ ‫‪32‬‬
‫فشاع قاس – عشبة مغربية – عش‬
‫‪-s.bona-nox‬‬ ‫‪rough bindweed‬‬
‫المغرب – فشاغ – العشبة – سار ساباريل‬
‫‪s.china‬‬ ‫‪sarsaparilla honduras‬‬
‫فشاغ صيني – عشبة – فشاع زرا‬
‫‪serenoa serrulata‬‬ ‫‪33‬‬
‫البلميط المنشاري – نخل قص‬ ‫‪saw palmetto‬‬

‫‪c.acutifolia‬‬ ‫‪34‬‬
‫سنامكي – سلمكي – سنة ملكي – ال‬
‫هندي – سنا امريكي السنا – قسا ‪ -‬مري‬ ‫‪c.angustifolia‬‬ ‫‪senna‬‬

‫‪c.senna‬‬
‫حشيشة الكبد – حشيشة القل‬
‫هيوفاريقون – داذي رومي –منسية – عش‬ ‫‪35‬‬
‫لسع – عشبة شياط‬ ‫‪hypericum perforatum‬‬ ‫‪st. john's wart‬‬
‫اصابع صفر – كركرم – زعفران الهن‬
‫مايران ‪ -‬ه‬ ‫‪curcuma longa‬‬ ‫‪tumeric curcuma‬‬ ‫‪36‬‬
‫النردبن الطبي – سنبل – حشيشة القط‬
‫ناريدن مخز‬ ‫‪valeriana officinalis‬‬ ‫‪cat's valerian‬‬ ‫‪37‬‬
‫يوهيم‬
‫‪pausinystalia yohimbe‬‬ ‫‪yohim be/yohimbine‬‬ ‫‪38‬‬
‫سنفتي‬
‫‪symphytum sp.‬‬ ‫‪comfrey‬‬ ‫‪39‬‬

‫حشيشة السعال – فرفارة – طارد سعال‬ ‫‪coitsfoot‬‬ ‫‪40‬‬

‫طفوف كرمة – دوسة الح‬ ‫‪tussilago farfara‬‬
‫‪cough wort‬‬
‫جعدة – كمادريوس – طوقريونمخزن‬
‫خمادريو‬ ‫‪teucrium chamaedrys‬‬ ‫‪gennander,groud oak‬‬ ‫‪41‬‬
‫دغل اج‬
‫‪larrea divaricata‬‬ ‫‪chaparral‬‬ ‫‪42‬‬
‫السافراس – نبات امريكي من الفص‬
‫العا‬ ‫‪sassafras albidum‬‬ ‫‪sassafras‬‬ ‫‪43‬‬
 aconite 44
‫بيش موش – خانق الذئب – قاتل النم‬
monkes hood
‫اقونيط – كونيطن – بيش البير – اكون‬
‫هرمي – بيشا – طوارة – بيس حد‬ aconitum napellus
wolfs bane

blue rocket,friar's cap.

‫نعناع الماء –فوذنج فلية – فليحا – ن‬ mentha pulegium 45

‫الحقل – نعناع الماء المري‬ pennyroyal
hedeoma pulegioides
‫عنب الذ‬
phytolacca americana poke 46
‫غذاء ملكات الن‬
apis mellifera (honey bee royal jelly 47

some herbs were not found in references:

* bromelain
* dong quai
* gossypol
* karela
* kelp
* pall d' areo
* shankapulsshpi
* siberian ginseng
* u zara root
* worm wood
* pyehnogenol
* cranberry
* jin bu huan
 www.alam-tany.com

acknowledgement
i would like to express my deepest gratitude to professor ahmed
abdel salam, professor of pharmacology, ain-shams university, for
his generous guidance & great effort in helping me with the
material included in this text.
my cordial thanks are due to doctor samia salah; head of the drug
policy & planning centre, ministry of health; & her team for the
valuable information they supplied & which enriched the text.

the author

www.alam-tany.com